The kynurenine pathway in body and brain : relation with physical exercise and mental health by Trepci, Ada
From Department of Physiology and Pharmacology  
Karolinska Institutet, Stockholm, Sweden 
THE KYNURENINE PATHWAY IN BODY 
AND BRAIN - RELATION WITH PHYSICAL 






All previously published papers were reproduced with permission from the publisher. 
Published by Karolinska Institutet. 
Printed by Universitets service US-AB, 2021 
© Ada Trepci, 2021 
ISBN 978-91-8016-229-6  
Cover by Esra Trepci 
The kynurenine pathway in body and brain - relation 
with physical exercise and mental health 
THESIS FOR DOCTORAL DEGREE (Ph.D.)  
By 
Ada Trepci 
The thesis will be defended in public at Karolinska Institutet, Biomedicum 1, Stockholm, 
Sweden, 20th of May 2021, 13:00 
Principal Supervisor: 
Professor Sophie Erhardt  
Karolinska Institutet 
Department of Physiology and Pharmacology 
Division of Neuropsychoimmunology  
 
Co-supervisor(s): 
Dr. Kristian Sandberg  
Uppsala University  
Department of Medicinal Chemistry   
Science for Life Laboratory  
 
Professor Tomas Venckunas  
Lithuanian Sports University  
Institute of Sport Science and Innovations  
 
Opponent: 
MD, PhD, DSc(med), Professor Gregers Wegener  
Aarhus University, Denmark  
Department of Clinical Medicine   
Translational Neuropsychiatry Unit   
 
Examination Board: 
Associate Professor Mia Lindskog 
Uppsala University  
Department of Neuroscience  
Division of Medical Neurobiology  
 
Professor Bo Runeson  
Karolinska Institutet  
Department of Clinical Neuroscience  
Division of Centre for Psychiatry Research  
 
Associate Professor Daniel Globisch  
Uppsala University  
Department of Chemistry - BMC  


























































The shape of word cloud is a face mask, chosen as representative symbol of COVID-19 pandemic, 
period during which this thesis was finalized.  
 






The kynurenine pathway of tryptophan degradation is the focus in a variety of research fields 
and several of the metabolites produced along the pathway are suggested as future biomarkers. 
Growing interest in a better understanding of the physiological and the pathophysiological 
importance of kynurenine pathway metabolites is followed by the need for a robust, sensitive 
method that can quantify multiple metabolites simultaneously. In the present thesis, the first 
aim was to develop and validate robust and sensitive methods for the analysis of kynurenine 
pathway metabolites in body and brain. Our method thus allows for simultaneous quantification 
of low concentrations of tryptophan, kynurenine, kynurenic acid (KYNA), 3-
hydroxykynurenine (3-HK), xanthurenic acid (XA), 3-hydroxyanthranilic acid (3-HANA), 
quinolinic acid (QUIN), picolinic acid (PIC), nicotinic acid (NA) and nicotinamide (NAA) in 
human cerebrospinal fluid (CSF) and plasma. In addition, our new method clearly separates 
the peaks of the isomers, PIC and NA. Moreover, metabolites of the kynurenine pathway have 
been linked to the pathophysiology of bipolar disorder and suicide. In this thesis, we thus 
analyzed the concentrations of kynurenine pathway metabolites in the CSF of suicide 
attempters and patients with bipolar disorder. All patients were stratified into groups according 
to their history of suicide behavior. As previously reported, we found a reduced CSF PIC/QUIN 
ratio in suicide attempters. Furthermore, patients with bipolar disorder and a history of suicide 
behavior had lower CSF PIC concentrations than those without, giving further support for the 
hypothesis that low CSF PIC is a predictor of suicidality vulnerability. A negative correlation 
between an ACMSD genetic variant and the CSF PIC/QUIN ratio in patients with bipolar 
disorder with a history of suicide behavior was discovered, suggesting that polymorphism in 
ACMSD is linked to excess QUIN formation at the expense of PIC. In patients with bipolar 
disorder, we also found elevated CSF kynurenine/tryptophan ratio, KYNA, and PIC 
concentrations clearly demonstrating induction of the kynurenine pathway in these patients. 
In the process of developing biomarkers, it is also important to understand if and how daily 
activity, such as physical exercise affects their concentration. The majority of exercise studies 
investigating kynurenines published so far have focused on a few kynurenine metabolites, and 
most often not taken into consideration the exercise habit of the participants that might affect 
the results. In the last part of this thesis, we thus investigated how different types of exercise 
influence central and peripheral levels of kynurenine pathway metabolites. Specifically, we 
investigated how one bout of sprint interval exercise (SIE) affects plasma kynurenine pathway 
metabolites of healthy subjects belonging to different age groups. In detail, the SIE session 
consisted of 6 repetitions of 30-seconds all-out cycling with 4-minutes passive recovery periods 
in between. Moreover, in another cohort of healthy subjects with a background of different 
exercise habits, we investigated how aerobic exercise affected kynurenine pathway metabolites 
and immune markers in plasma and CSF. In this study, participants were divided into two 
groups based on their existing level of physical activity habits. One group performed an acute 
intense exercise program for four days (two days of 30 minutes high-intensity interval training, 
and two days of running for at least 60 minutes) and the second training group performed 30 
minutes of running, three times weekly, for 4 weeks.  
The results clearly show that both types of exercise tested (aerobic and anaerobic) influence 
kynurenine pathway metabolites. We found that plasma levels of kynurenine increased 1 hour 
after the SIE session in healthy elderly subjects, while levels of KYNA increased after 24 hours. 
We further found that acute exercise intervention, increased the CSF levels of KYNA, 3HK, 
and PIC, while tryptophan and kynurenine remained unchanged. Furthermore, in the training 
group, the CSF kynurenine/tryptophan ratio increased. Tryptophan and kynurenine, on the 
other hand, decreased significantly after acute exercise, while KYNA, 3-HK, QUIN, and PIC 
in the plasma did not change in any of the groups. Some immune markers showed a tendency 
towards an increase in both plasma and CSF but were not statistically significant. In plasma, 
kynurenine and PIC levels were correlated with aberrant immune markers profile. While in 
CSF, kynurenine and QUIN levels, and also the ratio of kynurenine/tryptophan were associated 
with immune protein marker profiles. One important finding was the positive correlation 
between PIC levels in plasma and CSF.  
In the present thesis, we have developed a novel method for the simultaneous quantification of  
kynurenine pathway metabolites. We also confirm that the brain kynurenine pathway in 
patients with bipolar disorder is activated as well as we show data supporting that low PIC 
might indicate vulnerability for suicidal behavior. Furthermore, we confirm that both central 





LIST OF SCIENTIFIC PAPERS 
 
 
I. Lilly Schwieler, Ada Trepci, Stanislaw Krzyzanowski, Sigurd Hermansson, 
Mathias Granqvist, Fredrik Piehl, Tomas Venckunas, Marius Brazaitis, 
Sigitas Kamandulis, Daniel Lindqvist, A. Daniel Jones, Sophie Erhardt, Lena 
Brundin. A novel, robust method for quantification of multiple 
kynurenines pathway metabolites in the cerebrospinal fluid. Bioanalysis, 
12(6):379-392, 2020 
 
II. Ada Trepci, Carl M. Sellgren, Erik Pålsson, Lena Brundin, Neda 
Khanlarkhani, Lilly Schwieler, Mikael Landén, Sophie Erhardt. Central 
levels of tryptophan metabolites in subjects with bipolar disorder. 
European Neuropsychopharmacology, 43:52-62, 2021  
 
III. Ada Trepci, Sophie Imbeault, Victoria L. Wyckelsma, Håkan Westerblad, 
Sigurd Hermansson, Daniel C. Andersson, Fredrik Piehl, Tomas Venckunas, 
Marius Brazaitis, Sigitas Kamandulis, Lena Brundin, Sophie Erhardt, Lilly 
Schwieler. Quantification of plasma kynurenine metabolites following 
one bout of sprint interval exercise. International Journal of Tryptophan 
Research, 13:1178646920978241, 2020 
 
IV. Josef Isung, Mathias Granqvist, Ada Trepci, Jesse Huang, Lilly Schwieler, 
Marie Kierkegaard, Sophie Erhardt, Jussi Jokinen, Fredrik Piehl. Differential 
effects on blood and cerebrospinal fluid immune protein markers and 
kynurenine pathway metabolites from aerobic physical exercise in 






1 INTRODUCTION ......................................................................................................... 7 
1.1 The kynurenine pathway of tryptophan degradation ........................................... 7 
1.1.1 Kynurenines in body and brain ................................................................ 9 
1.1.2 Immune-induced activation of the kynurenine pathway ....................... 11 
1.2 Analysis of kynurenines and challenges ............................................................ 12 
1.3 Psychiatric disorders and the kynurenine pathway ............................................ 13 
1.3.1 Bipolar disorder ...................................................................................... 13 
1.3.2 Suicide .................................................................................................... 17 
1.4 Physical exercise impact on the kynurenine pathway ....................................... 19 
2 RESEARCH AIMS ...................................................................................................... 23 
3 MATERIALS AND METHODS ................................................................................ 25 
3.1 Ethical considerations ........................................................................................ 25 
3.2 Human subjects .................................................................................................. 25 
3.2.1 Stability cohort ....................................................................................... 25 
3.2.2 Suicide cohort ......................................................................................... 25 
3.2.3 St. Göran Bipolar Project ....................................................................... 26 
3.2.4 Healthy subjects ..................................................................................... 27 
3.3 CSF and plasma .................................................................................................. 28 
3.3.1 Lumbar puncture .................................................................................... 28 
3.3.2 Plasma isolation ..................................................................................... 28 
3.4 UPLC–MS/MS – kynurenine metabolites analysis in CSF and plasma ........... 28 
3.4.1 Chemicals and reagent ........................................................................... 28 
3.4.2 Standard solutions .................................................................................. 29 
3.4.3 Analysis .................................................................................................. 29 
3.4.4 Methods validation ................................................................................. 32 
3.4.5 Sample preparation ................................................................................ 34 
3.4.6 Stability test ............................................................................................ 34 
3.5 HPLC – analysis of neurotransmitters ............................................................... 35 
3.5.1 Chemicals and reagents .......................................................................... 35 
3.5.2 Standard solutions .................................................................................. 35 
3.5.3 Analysis .................................................................................................. 35 
3.5.4 CSF sample preparation ......................................................................... 36 
3.6 Proximity extension assay - immune markers analysis ..................................... 36 
3.7 Genotyping ......................................................................................................... 36 
3.8 Exercise protocols .............................................................................................. 37 
3.8.1 Sprint interval exercise ........................................................................... 37 
3.8.2 Aerobic training ..................................................................................... 37 
3.9 Data analysis ....................................................................................................... 38 
4 RESULTS AND DISCUSSION ................................................................................. 41 
4.1 UPLC–MS/MS method validation (Paper I, III) ............................................... 41 
4.1.1 Calibration curve linearity ..................................................................... 41 
4.1.2 Lower limit of quantification ................................................................. 42 
4.1.3 Selectivity and specificity ...................................................................... 42 
4.1.4 Accuracy and precision .......................................................................... 44 
4.1.5 Matrix effect ........................................................................................... 45 
4.1.6 Stability .................................................................................................. 48 
4.2 Kynurenine metabolites in the CSF of patients with bipolar disorder and 
suicide attempters (Paper I, II) ........................................................................... 54 
4.2.1 Decreased ratio PIC/QUIN in the CSF of suicide attempters ............... 54 
4.2.2 Kynurenine metabolites in the CSF of patients with bipolar 
disorder ................................................................................................... 56 
4.2.3 Decreased levels of CSF PIC in patients with bipolar disorder with 
suicidal behavior .................................................................................... 58 
4.2.4 Associations between pharmacological treatment and kynurenine 
metabolites in CSF of patients with bipolar disorder ............................ 60 
4.2.5 Associations between CSF kynurenine metabolites and symptoms ..... 63 
4.2.6 Common genetic variation in ACMSD and suicidal behavior ............. 63 
4.3 Kynurenine metabolites in the CSF and plasma of healthy subjects 
following physical exercise (Paper III, IV) ....................................................... 64 
4.3.1 Sprint interval training ........................................................................... 64 
4.3.2 Aerobic exercise ..................................................................................... 66 
4.3.3 Neurotransmitters in the CSF of healthy subjects ................................. 69 
4.3.4 Immune markers in the CSF and plasma of healthy subjects ............... 69 
4.3.5 Relation CSF-plasma of kynurenine metabolites and immune 
markers in healthy subjects .................................................................... 71 
5 GENERAL DISCUSSION .......................................................................................... 73 
6 ACKNOWLEDGEMENTS ........................................................................................ 77 








































α-7 nicotinic acetylcholine 
Anthranilic acid 
2-amino 3-carboxymuconic semialdehyde 
2-amino 3-carboxymuconate 6-semialdehyde decarboxylase 
Arylhydrocarbon receptor  
a-amino-3-hydroxy-5-methylisoxazole-4-propionate 
Blood brain barrier  
Central nervous system 
Cerebrospinal fluid  
Coefficient of variation  
Diagnostic and Statistical Manual of Mental Disorders 
Ethylenediaminetetraacetic acid  
European Medicines Agency 
Positive electrospray ionization mass spectrometry 
Food and Drug Administration 
False discovery rate  
γ-aminobutyric acid 
General Data Protection Regulation  
G protein-coupled receptor  
Genome-wide association studies 
Human immunodeficiency virus  
High performance liquid chromatography  
Half maximal inhibitory concentrationn 


































Inter Quartile range  
Internal standard  




Lower limit of quantification  
Limit of detection  
Lipopolysaccharide  
Montgomery-Åsberg Depression Rating Scale 
Monocyte chemotactic protein-1 
Mini International Neuropsychiatric Interview 
Major depressive disorder  
Matrix metalloproteinase  
Multiple reaction monitoring 
Messenger ribonucleic acid  
Multiple sclerosis  
Nicotinic acid  
Nicotinamide  
Nicotinamide adenine dinucleotide 
N-methyl-D-aspartate 
Normalized protein expression 
O-phthaldialdehyde   
Proximity extension assay 




Rating of Perceived Exertion  
Relative standard deviation  

















Structured Clinical Interview 
Standard deviation  
Sprint interval exercise  
Signal to noise ratio  
Single nucleotide polymorphism 
Tick-borne encephalitis   
Tryptophan 2,3 dioxygenase 
Total ion current  
Tumor necrosis factor  
Ultrahigh-performance liquid chromatography / tandem mass spectrometry 
Vascular endothelial growth factor  
World Health Organization   
Xanthurenic acid 










1.1 The kynurenine pathway of tryptophan degradation  
In mammals, tryptophan can be catabolized into serotonin and melatonin as well as via the 
kynurenine pathway. Around 90-95% is degraded through the latter pathway and is thus, 
considered as the primary route of degradation from a quantitative perspective (Leklem, 1971; 
Guidetti et al., 1995; Schwarcz & Stone, 2017) (Figure 1). 
 
Figure 1. The kynurenine pathway of tryptophan degradation  
(Created with BioRender.com) 
 
8 
The kynurenine pathway of tryptophan degradation has gained a lot of attention during the last 
decades because first, the kynurenine pathway produces the nicotinamide adenine dinucleotide 
(NAD+) which is the energy for the cells, and plays a crucial role in the wellbeing of humans, 
and second, several neuroactive metabolites are produced along kynurenine pathway.  
Kynurenine pathway begins with the hydroxylation of tryptophan into N-formylkynurenine by 
enzymes: indolamine 2,3 dioxygenase 1 (IDO1) (Hayaishi, 1976), indolamine 2,3 dioxygenase 
2 (IDO2) (Ball et al., 2009) and/or tryptophan 2,3 dioxygenase (TDO2) (Hayaishi et al., 1957;  
Hayaishi, 1993). It continues with the hydrolyzation of N-formylkynurenine into kynurenine 
by the kynurenine formamidase (Knox & Mehler, 1950). Then kynurenine is further 
catabolized into three products, by different enzymes:  
1. Kynureninase, hereby producing anthranilic acid (AA). 
2. Kynurenine 3 monooxygenase (KMO), producing 3-hydroxykynurenine (3-HK), a 
free radical generator. 
3. By irreversible transformation through four isoforms of enzymes kynurenine 
aminotransferase (KATs: KAT: I, II, III, IV), producing the end-metabolite 
kynurenic acid (KYNA) (Han et al., 2010).  
 
Both 3-HK and AA are catabolized to 3-hydroxyanthranilic acid (3-HANA), through the 
enzyme kynureninase or via non-enzymatic oxidation, respectively. 3-HK might also be 
catabolized to xanthurenic acid (XA) through KATs. Subsequently 3-HANA, through the 
enzyme 3-hydroxyanthralinate 3,4-dioxigenase (3-HAAO) is converted to 2-amino 3-
carboxymuconic semialdehyde (ACMS) or through non-enzymatic oxidation to cinnabarinic 
acid (Christen et al., 1992). ACMS serves as substrate for 2-amino 3-carboxymuconate 6-
semialdehyde decarboxylase (ACMSD) and 2-aminomuconic 6-semialdehyde is generated, 
which spontaneously converts to picolinic acid (PIC) (Mehler, 1956). When the enzyme 
ACMSD is saturated, missing, or less active, the spontaneous formation of quinolinic acid 
(QUIN) from ACMS is enhanced. Finally, QUIN is catabolized by quinolinate 
phosphoribosyltransferase, leading to NAD+. The production of NAD+ via the kynurenine 
pathway is inversely proportional to the activity of the enzyme ACMSD  (Shibata & 
Fukuwatari, 2015). The kynurenine pathway of tryptophan degradation is the essential route 
for de novo synthesis of NAD+ in mammalian cells. However, in cases of diets poor in 
tryptophan, the de novo NAD+ synthesis decreases, and alternatively, NAD+ is recycled by 
nicotinic acid (NA) and nicotinamide (NAA), well known as “salvageable precursors” (Bogan 
& Brenner, 2008; Braidy et al., 2019). 
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1.1.1 Kynurenines in body and brain  
All kynurenine pathway enzymes are present both in body and brain, however, generated 
metabolites are tissue and cell specific (Platten et al., 2019). Notably, the relative abundance of 
the metabolites produced along the pathway, in body and in brain, is thought to be regulated at 
various interdependent levels (Badawy, 2017). Thus, the concentration of kynurenine 
metabolites in the periphery may affect brain levels of some of the kynurenine metabolites. 
The majority of tryptophan in the periphery is metabolized in the liver but tryptophan is also 
transported into the brain through the blood-brain barrier (BBB) by the large neutral amino 
acid transporter. Tryptophan competes with other large amino acids, such as leucine, 
isoleucine, tyrosine, methionine, and valine when entering the brain. Thus, the amount of 
tryptophan entering the brain depends on plasma tryptophan concentration as well as its relative 
concentration compared to the concentrations of other large amino acids (Fernstrom, 1983).  
Kynurenine can be transported through the neutral amino acid transporter over the BBB, but 
can also be produced locally in the brain (Gál & Sherman, 1980; Ramos-Chávez et al., 2018). 
In physiological conditions, periphery provides approximately 60% of the kynurenine present 
in the brain (Gál & Sherman, 1980; Fukui et al., 1991). In the brain, kynurenine is produced by 
neurons,  astrocytes, microglia, microvascular endothelial cells, and macrophages (Guillemin 
et al., 2007). In the periphery, kynurenine is produced in the lungs, placenta, stomach, 
intestines, spleen, kidney and liver (Stone, 1993; King & Thomas, 2007). In low micromolar 
concentration (Opitz et al., 2011), kynurenine has an affinity for the aryl hydrocarbon receptors 
(AhR). AhR is expressed in peripheral organs, such as adipose tissue, lungs, liver, and also in 
the brain. Immune regulation, cell differentiation and tumorigenesis are affected by the AhR 
(Mezrich et al., 2010; Opitz et al., 2011; Yamamoto et al., 2019). 
KYNA is produced by a variety of peripheral cells and organs, such as the liver, kidney, and 
heart, and is detected in multiple biological fluids, including urine, blood, milk, cerebrospinal 
fluid (CSF), saliva, gastric juice, amniotic fluid, pancreatic juice and bile (Milart et al., 1999; 
Kuc et al., 2006; Paluszkiewicz et al., 2009; Milart et al., 2019). KYNA has a polar structure 
and does not easily pass the BBB. One rodent study showed that in case of exceedingly high 
levels of KYNA in the periphery and in case the BBB is compromised,  KYNA can enter the 
brain (Scharfman et al., 2000). However, the influx rate of which KYNA enters the brain from 
the periphery is very low and is calculated to be 0.0023 nmol/h/g (Fukui et al., 1991). In the 
brain, KYNA is mostly produced by astrocytes (Kiss et al., 2003; Rossi et al., 2008). KYNA is 
known for having neuroprotective properties (Moroni, 1999). KYNA binds to a wide range of 
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different receptors. When KYNA is present in low concentrations (IC50: 8-15 µM), it acts as 
an antagonist at the glycine binding site of the N-methyl-D-aspartate (NMDA) receptor (Birch 
et al., 1988) and when KYNA is present in high concentrations (IC50: 0.2-0-5 mM) it acts as 
an antagonist at the glutamate recognition site of the same receptor (Kessler et al., 1989). 
KYNA shows antagonistic properties also to the kainate and a-amino-3-hydroxy-5-
methylisoxazole-4-propionate (AMPA) receptors (Perkins & Stone, 1982; Kessler et al., 1989). 
Furthermore, KYNA is suggested to be a non-competitive inhibitor of α-7 nicotinic 
acetylcholine (α7nACh) receptor (IC50: 7 µM) (Hilmas et al., 2001), although some 
controversies regarding this remain (Stone, 2020). Also, KYNA shows agonistic properties to 
other receptors, such as AhR (DiNatale et al., 2010) and G protein-coupled receptor 35 
(GPR35) (Wang et al., 2006).  
In the periphery, QUIN is produced in several organs and can be detected in biological fluids 
such as urine, blood, and CSF. Central QUIN originates from local sources in the brain; mainly 
microglial cells and macrophages that have crossed the BBB (Guillemin, 2012). QUIN is an 
excitotoxic NMDA receptor agonist (Stone & Perkins, 1981; Schwarcz et al., 2012), known to 
be neurotoxic mainly through two mechanisms: 1. increasing glutamate release and 2. 
inhibiting glutamate uptake (Guillemin et al., 2001). Rodent studies showed that the affinity of 
QUIN to NMDA receptor is affected also by the endogenous iron levels (Št’Astny et al., 1999). 
The half-life of QUIN is relatively short, around 20 minutes (Bryleva & Brundin, 2017). 
PIC can be found in human CSF and plasma, as well as in human milk, pancreatic juice and 
intestinal homogenates. The ability of PIC to chelate copper, iron and other metals is its most 
well-known physiological function (Grant et al., 2009). PIC in the brain possesses neuroactive 
properties. PIC can act as an agonist of strychnine-sensitive glycine receptors in spinal neurons, 
in addition to having a protective effect in the brain (Tonohiro et al., 1990; 1997). Thus, PIC is 
thought to mitigate the neurotoxicity caused by QUIN by inhibiting glutamate release from the 
presynaptic neurons (Vrooman et al., 1993; Beninger et al., 1994). While neurotoxicity caused 
by QUIN might be blocked by PIC, neuroexcitatory effects of QUIN are not affected 






1.1.2 Immune-induced activation of the kynurenine pathway  
The kynurenine pathway of tryptophan degradation is strongly influenced by the immune 
system and can be activated by a variety of inflammatory parameters. For example, the rate-
limiting enzyme of the pathway IDO1 can be triggered by tumor necrosis factor (TNF)-α, TNF- 
β, interferon (INF)-α, INF-β, and INF-γ (Guillemin et al., 2001; Bergström et al., 2002; 
Wichers & Maes, 2004; King & Thomas, 2007; Munn & Mellor, 2016). IDO1 is also induced 
by other cytokines, such as interleukins (IL), for example, IL-1α, IL-6, and IL-10 (Babcock & 
Carlin, 2000, Yanagawa et al., 2009; Hayley, 2011). TDO2 is instead induced by IL-1β (Urata 
et al., 2014; Sellgren et al., 2016) and is additionally regulated by corticosteroids (Campbell et 
al., 2014). Another important enzyme of the pathway, KMO, which leads to the excitatory 
branch of the pathway is activated by immune markers (Garrison et al., 2018; Lu et al., 2020). 
For instance, KMO expression is elevated by IL-1β (Zunszain et al., 2012).   
Several experimental studies have shown that challenging the immune system induces the 
kynurenine pathway. Thus, dual lipopolysaccharide (LPS) injections of 0.83 mg/ kg increase 
the levels of kynurenine and KYNA in the mouse brain and serum, as well as QUIN in the 
brain (Larsson et al., 2016; Tufvesson-Alm et al., 2020). Levels of KYNA are also increased 
in mice brain after a single dose of 2 mg/kg of LPS but not from the dose of 0.32mg/ kg and 
0.8 mg/kg (Tao et al., 2020). Furthermore, LPS induces IDO1, resulting in decreased 
tryptophan and increased kynurenine levels in mouse plasma (O’connor et al., 2009). 
Following LPS treatment, KMO expression rises along with an increase in brain IL-6 (Connor 
et al., 2008; Molteni et al., 2013). LPS can also increase the levels of 3-HK in the mouse brain, 
both in the cortex and hippocampus (Tao et al., 2020).  
Clinical studies have shown that the kynurenine pathway is activated in several infectious 
diseases. Thus, patients with tick-borne encephalitis (TBE) have elevated CSF levels of KYNA 
and KYNA correlates with the severity of the disease (Holtze et al., 2012). On the other hand, 
children (median age 142 months old) with TBE do not show changes in levels of KYNA and 
kynurenine in the CSF (Wickström et al., 2021). Elevated levels of CSF KYNA were also seen 
in subjects with herpes simples virus type 1 encephalitis (Atlas et al., 2013) or human 
immunodeficiency virus type  (HIV) (Atlas et al., 2007). Moreover, IDO1 activity is elevated 
in the plasma of subjects with HIV (Favre et al., 2010). In addition, children with malaria have 




1.2  Analysis of kynurenines and challenges  
Metabolites produced along the kynurenine pathway are gaining more and more attention and 
are suggested to have crucial roles both in health and in diseases, such as cancer, infections, 
neurodegenerative diseases as well as neurological, cardiovascular, immunological, and 
psychiatric disorders (Widner et al., 2000; Atlas et al., 2007; Olsson et al., 2010; Linderholm 
et al., 2012; Schwarcz et al., 2012; Polyzos & Ketelhuth, 2015; Rajda et al., 2015; Schwieler 
et al., 2016; Erhardt et al., 2017; Majlath et al., 2018; Platten et al., 2019).  
Most studies so far have focused on a limited number of the metabolites in human CSF and 
plasma. In order to get a more comprehensive picture of the regulation and activity of the 
kynurenine pathway, both in physiological and pathophysiological conditions, it is important 
to simultaneously quantify several kynurenine metabolites using the same method. When 
establishing such a method, there are a few things to consider and challenges that arise along 
the way.  
First, the endogenous concentration of the kynurenine metabolites ranges from nanomolar to 
micromolar (Linderholm et al., 2012; Schwarcz et al., 2012; Kegel et al., 2014; Brundin et al., 
2016). In addition, the concentration of a specific metabolite is also tissue- and/or biological 
fluid-specific as well as health- or disease-state-specific. For example, tryptophan in the CSF 
and plasma is present at micromolar concentrations while kynurenine in CSF is present at 
nanomolar concentrations but in plasma is in the micromolar range. The other metabolites, such 
as KYNA, 3-HK, QUIN, 3-HANA, XA, PIC, NA, NAA are found in nanomolar concentrations 
both in CSF and in plasma.  Thus, for some metabolites, a lower sensitivity is needed for 
detection, while for others, a higher sensitivity should be maintained.  
Second, the chemical structures of the kynurenine metabolites are closely related, which makes 
it impossible to use antibody-based detection methods. For instance, two of the kynurenine 
metabolites, PIC and NA are isomers.  
Third, biological human samples, such as CSF and plasma, on a practical level, undergo at least 
one freezing and thawing cycle before being analyzed. In addition, routines in the clinic may 
also lead to samples standing on the bench at room temperature before being frozen. Such 
handling may affect the concentrations of kynurenines. Knowing the stability of kynurenine 
pathway metabolites, in order to avoid those variances, is important when reporting high 
quality data both in the clinic and in experimental research. However, the stability of 
kynurenine pathway metabolites has previously been studied. KYNA has been shown to be 
stable in human urine up to 36 h when stored at 4°C (Furlanetto et al., 1998). In acidified 
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authentic human urine, tryptophan, kynurenine, KYNA, and AA have been shown to be stable 
for up to 3 cycles of freeze-thaw and up to 90 days at -20° (Yan et al., 2017). AA in human 
blood is stable for only 30 min at room temperature, while tryptophan, kynurenine, KYNA, 3-
HK, and XA are stable for up to 4 hours (Boulet et al., 2017).  
To date, tryptophan and kynurenine have mainly been analyzed using high performance liquid 
chromatography (HPLC) with electrochemical detection, ultraperformance liquid 
chromatography (UPLC), gas chromatography-mass spectrometry (GS-MS), and liquid 
chromatography-mass spectrometry (LC-MS) (Linderholm et al., 2012; Notarangelo et al., 
2012; Jones et al., 2015; Flieger et al., 2018).  KYNA has mainly been analyzed using HPLC  
(Shibata, 1988; Swartz et al., 1990; Jauch et al., 1993; Erhardt et al., 2001) with fluorescence 
detection and QUIN and PIC using GC-MS (Smythe et al., 2002; Erhardt et al., 2013; Brundin 
et al., 2016).  
Thus, a sensitive, robust, and specific method for simultaneously detection and quantification 
of multiple kynurenine metabolites in human CSF and plasma has been lacking.  
Given that kynurenine pathway metabolites are suggested to play a role in the pathophysiology 
of psychiatric disorders it is of high interest to investigate their relation between CSF and 
plasma. Since the CSF is not easily accessible, it is a clinical advantage for psychiatric disorders 
to have blood biomarkers.  In addition, since kynurenines might have the potential as future 
biomarkers used in clinical situations, there is a need to investigate how they are affected by 
confounding factors. Importantly, many studies show that physical exercise affects 
kynurenines in the periphery (Lim et al., 2021). Currently, there is a need for understanding 
how physical exercise affects kynurenine pathway metabolites centrally, and to what extent 
this is reflected in the periphery.  
 
1.3 Psychiatric disorders and the kynurenine pathway  
1.3.1 Bipolar disorder  
Bipolar disorder is a severe chronic psychiatric disease. Based on data from the World Health 
Organization (WHO) up to 60 million people suffer from the disorder that is characterized by 
mood disturbances, with recurring episodes of either mania (elevated mood, reduced need for 
sleep, increased energy) or hypomania (milder symptoms than mania) and episodes of 
depression (low mood, decreased energy, loss of pleasure) (Phillips & Kupfer, 2013). Between 
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the depressive and manic episodes, the majority of patients experience a neutral mood, referred 
to as the euthymic state. According to the latest version of the main diagnostic manual for 
psychiatric disorders, Diagnostic and Statistical Manual of Mental Disorders fifth edition 
(DSM-V) there are four main subtypes of bipolar disorders (American Psychiatric Association, 
2013):  
1. Bipolar disorder type I – at least one episode of mania, that might have been preceded 
or followed by an episode of hypomania or an episode of major depression. 
2. Bipolar disorder type II – at least one episode of hypomania and one major depressive 
episode (and no episodes of mania).  
3. Cyclothymic disorder – hypomanic symptoms and depressive symptoms, but not full 
episodes of hypomania and episodes of major depression.  
4. Bipolar disorder not otherwise specified – hypomanic and depressive–like episodes, 
that might change rapidly, but do not correspond to bipolar disorder type I, to bipolar 
disorder type II or cyclothymic disorder. 
The diagnosis of bipolar disorder is based on symptomatology and clinical phenomenology, 
rather than on underlying biological mechanisms. To date, unfortunately, there are no 
biomarkers developed, neither for predicting and diagnosing the disorder nor for evaluating 
the treatment response. The lifetime prevalence of bipolar disorder is estimated to be 2.4% 
and the one-year prevalence is estimated to be 1.5% (Merikangas et al., 2011). The disease 
is associated with increased morbidity and mortality (Merikangas et al., 2011). Indeed, 
patients with bipolar disorder have a lifespan reduction compared to the general population 
(Crump et al., 2013). Suicide occurs often among patients with bipolar disorder. Around 30-
50% of patients with bipolar disorder attempt suicide and 15-20 % of them die by suicide 
(Dong et al., 2019). Importantly, bipolar disorder has the highest rate of suicide among all 
psychiatric diseases (Miller & Black, 2020).  
Pathophysiology  
What exactly causes the bipolar disorder is not known (Haggarty et al., 2021). However, several 
risk factors, such as genetics, environmental factors, substance abuse, and stressful life events, 
have been suggested (Craddock & Sklar, 2013; Uher, 2014). Bipolar disorder has a strong 
genetic component. The number of suggested risk genes is growing, especially in unbiased 
studies, such as Genome-wide association studies (GWAS). Some of the single nucleotide 
polymorphisms (SNPs) identified for bipolar disorder are reported to be in the genes involved 
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in calcium signaling (e.g., CACNA1C) (Ferreira et al., 2008; Green et al., 2013; Ruderfer et 
al., 2014), secretory pathways (LMAN2L) (Charney et al., 2017), cell cycle control (MAD1L1) 
(Hou et al., 2016), cytoskeleton (ANK3) (Ferreira et al., 2008; Charney et al., 2017), 
transcription factor activity (NFIX) (Ikeda et al., 2018) and neuronal connectivity (ODZ4) 
(Sklar et al., 2011; Green et al., 2013).  
Also, neurotransmitter imbalance in the brain can lead to bipolar disorder. Thus, dysregulations 
of monoamine neurotransmitters such as dopamine, serotonin, norepinephrine, and other 
neurotransmitters such as GABA and glutamate are suggested to be involved in the 
pathophysiology of bipolar disorder. The imbalance of monoamines in the central nervous 
system (CNS) is believed to relate to both manic and the depressive episodes. This hypothesis 
is supported by the mechanism of action of antidepressant medications (Fišar, 2013; Hillhouse 
& Porter, 2015), that act by increasing synaptic availability of serotonin and norepinephrine. 
Furthermore, dopaminergic system dysregulations might also be part of bipolar disorder 
(Brugue & Vieta, 2007; Gershon et al., 2007). A serotonin and norepinephrine deficiency plays 
a role in depression and mood and this has been proposed since the 1960’s  (Bunney & Davis, 
1965; Schildkraut, 1965). Furthermore, the balance of excitatory and inhibitory 
neurotransmitters, glutamate and GABA, is suggested to be of importance in the 
pathophysiology of bipolar disorder (Lan et al., 2009). Aberrant glutamate signaling in patients 
with bipolar disorder has been reported. Thus, a meta-analysis has revealed higher levels of 
glutamine and glutamate, measured by magnetic resonance spectroscopy, in the brain of 
patients with bipolar (Gigante et al., 2012). In addition, increased glutamate is also found in 
the post-mortem brain of bipolar patients (Lan et al., 2009). One study in patients with bipolar 
disorder, where both peripheral and central glutamate was measured, showed no differences 
when compared to healthy controls, whereas concentrations of glutamine, glycine, and D-
serine were increased and L-serine decreased in the periphery; no changes were seen centrally 
(Pålsson et al., 2015). Increased glutamate concentration has been also found in the plasma of 
patients with a mood disorder (Mauri et al., 1998). 
Brain immune activation is suggested to participate in the pathophysiology of bipolar disorder. 
According to studies revealed by St. Göran Bipolar Project, the pro-inflammatory cytokine, IL-
1b is found elevated in the CSF (Söderlund et al., 2011) of these patients. Recently, it has been 
reported that variations in the pro-inflammatory IL-1b gene examined concerning different 
brain region volumes did not differ between healthy controls and patients with bipolar disorder 
of the same cohort  (Strenn et al., 2021). In this thesis, bipolar disorder patients are the same 
subjects, but the data reported come from the 7-year follow-up.  
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Mounting evidence shows dysregulation of the kynurenine pathway in bipolar disorder. Indeed, 
elevated central levels of kynurenine and KYNA in subjects with bipolar disorder with a history 
of psychosis have been reported in several studies (Miller et al., 2004; Miller et al., 2006; 
Olsson et al., 2010; Lavebratt et al., 2014; Sellgren et al., 2016; Sellgren et al., 2019). 
Interestingly, CSF KYNA inversely correlates to depressive symptoms in patients with 
depression and suicidal behavior (Bay-Richter et al., 2015). An abnormal kynurenine pathway 
is also present in the periphery of patients with bipolar disorder (Bartoli et al., 2020) with 
decreased KYNA concentration being reported (Birner et al., 2017; Liu et al., 2018; Poletti et 
al., 2018; van den Ameele et al., 2020). Peripheral levels of QUIN in patients with bipolar 
disorder have been reported to be lower (Liu et al., 2018) or not changed when compared to 
healthy subjects (van den Ameele et al., 2020). To our knowledge, CSF QUIN has not been 
analyzed in bipolar disorder before. Plasma PIC levels are found to be lower in patients with 
bipolar disorder than in healthy subjects (Aarsland et al., 2019; Ryan et al., 2020).  
Treatment 
Pharmacological treatments for both bipolar disorder and psychiatric diseases, in general, have 
many limitations: the onset of treatment takes several weeks (Pjrek et al., 2009), many patients 
are resistant to the treatment, and the side effects reduce the patients’ daily life quality. The 
most commonly used drugs for bipolar disorder are mood stabilizers. Antidepressant drugs are 
often prescribed to patients with bipolar disorder. To date, anti-epileptic medications, 
valproate, and lamotrigine as well as second generation antipsychotic drugs, risperidone, and 
olanzapine are also used in the treatment of the bipolar disorder. Lithium is the most common 
mood stabilizer used and also has anti-suicidal effects through an unknown mechanism (Schou, 
2000). Lithium may act by stabilizing normal fluctuations in the transduction pathways of 
intracellular signals. Understanding the mechanism of action of lithium could lead to the 
identification of new drug targets for bipolar disorder. In the treatment of bipolar disorder, 
ebselen, has been shown to be a safer alternative to lithium (Singh et al., 2013). A recent study 
in rodents showed that acute administration of ebselen reduced levels of synaptic glutamate 






In the Merriam-Webster Dictionary, the definition of suicide is “the act or an instance of taking 
one´s own life voluntarily and intentionally”. Suicide counts for approximately 1.5% of all 
deaths worldwide (Fazel & Runeson, 2020). According to WHO, around 800 000 people 
commit suicide every year, which means every 40 seconds a suicide occurs in the world.  
Moreover, according to the WHO data, suicide was the third leading cause of death among 
young adults aged 15-19 in 2019. In addition, males commit suicide more often than females, 
conversely females attempt suicide more often than males. However, the proportion of males 
and females vary depending on the method used, help-seeking, and culture differences (Canetto 
& Sakinofsky, 1998; Nordentoft & Branner, 2008; Mergl et al., 2015; Schaffer et al., 2015). 
Today, the most important and highest risk factor for suicide is a previous suicide attempt 
(Suominen et al., 2004; Runeson et al., 2010; Goñi-Sarriés et al., 2018). The lack of biomarkers 
for suicidal ideation, makes it challenging to prevent.  
The majority of suicides are related to psychiatric disorders, like major depressive depression, 
bipolar disorder, and schizophrenia. Among all suicide cases, 3.4-14% suffer from bipolar 
disorder (Schaffer et al., 2015). 
Importantly, according to a review published in 2019, around 80% of subjects that committed 
suicide contacted the primary health care one year prior to suicide, 40% contacted the primary 
health care the last month of their life, while 31% contact the mental health care professionals 
during the last year of their life (Stene-Larsen & Reneflot, 2019). Thus, improving risk 
assessments and developing tests, biological or psychological, can help health care 
professionals to identify high-risk subjects. The development of robust and reproducible 
biomarkers for suicidality will save lives.  
Pathophysiology  
The pathophysiology behind suicide behavior is very complex and multifactorial. To date the 
biology behind is far from being clear, however, neurobiological systems and genetics are 
constantly being explored. Several risk genes have been identified in suicidality. For instance, 
the malfunctioning of the serotoninergic system in suicidality is thought to be genetically 
controlled (Bondy et al., 2006). Strong gene candidates are the ones that code for proteins 
involved in the regulation of serotonin neurotransmission, such as tryptophan hydroxylase, 
serotonin transporter, serotonin receptor, and monoamine oxidase  (MAO) A (Mann et al., 
2001; Antypa et al., 2013). 
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Almost three decades ago, elevated soluble IL-2 receptors were found in suicide attempters. 
This study was indeed one of the first pieces of evidence suggesting an imbalanced immune 
system in suicide (Nässberger et al., 1993). Later, chronic administration of the inflammatory 
cytokine INF-α has been shown to induce suicidal ideation (Dieperink et al., 2004). Many 
studies have reported aberrant levels of immune markers centrally, as well as in the periphery. 
For instance, elevated CSF IL-6  (Lindqvist et al., 2009) has been found in suicide attempters. 
Moreover, IL-8 and vascular endothelial growth factor (VEGF) is decreased in the CSF of 
suicide attempters (Isung et al., 2012). In the periphery, increased plasma IL-6 and TNF-α 
levels have been found in suicide attempters (Janelidze et al., 2011), while IL-2 was found to 
be decreased in plasma of suicide attempters (Janelidze et al., 2011; Isung et al., 2012). The 
presence of a compromised immune system is confirmed also by postmortem studies. Thus, 
IL-6 mRNA levels are higher in the prefrontal cortex of suicidal subjects (Pandey et al., 2012) 
as well as in the hippocampus (Hoyo-Becerra et al., 2013). In the prefrontal cortex of suicidal 
subjects mRNA levels of IL-1β and TNF-α are also higher (Pandey et al., 2012), while 
increased mRNA levels of IL-4 and IL-13 have been seen in orbitofrontal cortex brain tissue 
of subjects that committed suicide (Tonelli et al., 2008).  
Interestingly, in suicide attempters, a positive correlation has been found between CSF IL-6 
and CSF QUIN (Erhardt et al., 2013). In the same subjects, CSF levels of QUIN are elevated 
in suicide attempters (Erhardt et al., 2013). Another closely related metabolite, PIC is found to 
be reduced in the CSF of the same patients (Brundin et al., 2016). While QUIN returns to 
normal levels 6 months after the suicide attempt (Bay-Richter et al., 2015), levels of PIC are 
constantly low up to two years after the suicide attempt (Brundin et al., 2016). In those subjects 
no changes in CSF KYNA are present, nevertheless the ratio QUIN/KYNA is increased in 
suicide attempters compared to healthy subjects (Erhardt et al., 2013). Another important ratio, 
kynurenine/tryptophan, representing the rate limiting enzyme activity of the pathway is 
elevated in suicide attempters (Brundin et al., 2016). In addition, the minor C allele of SNP 
rs2121337, located in ACMSD, the enzyme limiting QUIN generation by competitive 
production of PIC, was more prevalent in suicide attempters compared to healthy controls 
(Brundin et al., 2016). Thus, PIC might be used as a biomarker indicating vulnerability for 







The lack of knowledge regarding pathophysiological mechanisms in suicidal behavior leads to 
limited options for pharmacological treatment. So far, ketamine, a glutamate signaling 
modulator involving NMDA and AMPA, is the most potent anti-suicidal treatment, its effects 
can be even be observed within hours. Several studies are being conducted in order to 
understand its mechanism of action. Studies from depressive-like behavior rodent genetic 
models (Flinders Sensitive Line (FSL) and Flinders Resistant Line (FRL) rats) show that one 
single injection of ketamine leads to rapid de novo spine density growth and interestingly 
normalized increased levels of NMDA receptor subunits (Treccani et al., 2019). Other 
mechanisms have also been suggested from experimental research. For example, brain-derived 
neurotrophic factor (BDNF) has been suggested to be part of the mechanisms (Garcia et al., 
2008; Autry et al., 2011). Activation of the mechanistic target of rapamycin (mTOR) pathways 
might also be one explanation of the ketamine mechanism of action (Liu et al., 2013; Zanos & 
Gould, 2018; Matveychuk et al., 2020).  
 
1.4 Physical exercise impact on the kynurenine pathway 
Accumulating evidence points to the beneficial effects of physical exercise on both health and 
disease. Interestingly, physical exercise has been shown to have a positive influence on the 
mental state of healthy subjects (Wollseiffen et al., 2016). Moreover, patients with the 
psychiatric disorder also show improvement in their symptoms following physical exercise. 
Specifically, physical exercise is a promising strategy to prevent the development of depressive 
disorders (Mammen & Faulkner, 2013; Schuch et al., 2018) and to improve depressive 
symptoms. Recently, the European Psychiatric Association suggested that physical activity 
should be part of standard prescriptions for treating depressive disorders  (Wegner et al., 2014; 
Khanzada et al., 2015).  
There is an increasing interest in the effects of physical exercise on the kynurenine pathway 
(Stubbs et al., 2018; Joisten et al., 2020). Indeed, an altered kynurenine pathway as reflected 
by increased or decreased kynurenine pathway metabolites has been suggested in several 
studies. These studies include different types of exercise. For example, aerobic exercise such 
as a marathon race (42.2 km) and 30 minutes of cycling or resistance exercise of 4 x 8-10 
repetitions at 70% one-repetition maximum (1RM) show decreased levels of plasma 
tryptophan in healthy subjects following such interventions (Lewis et al., 2010; Mudry et al., 
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2016; Joisten et al., 2020). A decrease in plasma tryptophan was also seen following 
incremental cycle ergometer exercise in both trained athletes (Strasser et al., 2016), and in 
patients with relapsing remitting multiple sclerosis (MS) (Bansi et al., 2018). Plasma 
tryptophan was also decreased in patients with type 2 diabetes when cycling for 30 minutes 
(Bansi et al., 2018) and in patients with gastroesophageal junction cancer receiving 
chemotherapy following 12 weeks and two weekly sessions of 30 - 34 minutes of cycling 
combined with resistance training  (Herrstedt et al., 2019). To our knowledge, only one study 
has reported increased levels of plasma tryptophan following 60 minutes of continuous 
treadmill exercise in elderly subjects (Melancon et al., 2014). Other studies have reported no 
change in plasma tryptophan levels of experienced triathletes participating in a half-ironman 
triathlon (Areces et al., 2015). No change in tryptophan was seen when healthy subjects 
performed endurance exercise of 45 minutes cycling (Joisten et al., 2020) when patients with 
major depressive disorder (MDD) and patients with somatization syndrome (mental disorder 
associated by multiple and recurring clinically significant complaints about somatic symptoms 
(Rief & Hiller, 1999)) followed one week of a daily 30 minutes fitness and stretching training 
(Hennings et al., 2013), and elderly people following a program consisting of 16 weeks of 
trademill training, thrice weekly, 6 km/ h for 45 minutes (Melancon et al., 2014). In addition, 
patients with pancreatic cancer following 6 months of two times/week supervised moderate to 
high progressive resistance exercise or unsupervised home-based resistance exercise did not 
show any changes of plasma tryptophan over time (Pal et al., 2021).  
Metabolites produced along the kynurenine pathway of tryptophan degradation, such as 
kynurenine, KYNA, and QUIN, have also been the focus of several studies investigating the 
effects of exercise.  
Moreover, both increased and decreased levels of kynurenine in plasma have been reported. 
Incremental cycle ergometer exercise increased levels of plasma kynurenine in trained athletes 
(Strasser et al., 2016). Also, 6 months of twice/week unsupervised homebased ressitance 
exercise increased levels of plasma kynurenine over time in patients with pancreatic cancer 
(Pal et al., 2021). On the other hand, 30 minutes of cycling decreased the plasma kynurenine 
levels in healthy and type 2 diabetes subjects (Mudry et al., 2016). Plasma kynurenine levels 
show no change in secondary progressive and relapsing remitting MS patients after incremental 
cycle ergometer exercise (Bansi et al., 2018), in healthy subjects performing resistance exercise 
or endurance exercise (45 min cycling) (Joisten et al., 2020), in healthy subjects, patients with 
MDD and patients with somatization syndrome following one week of daily 30 minutes fitness 
and stretching training (Hennings et al., 2013), in elderly at risk of dementia after a 10 weeks 
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program of physical training (a mixed program of endurance, balance, coordination, strength 
exercises) (Küster et al., 2017), in patients with mild to moderate depression following 12 
weeks of light, moderate or vigorous exercise (Millischer et al., 2017), in elderly subjects and 
in patients with gastroesophageal junction cancer receiving chemotherapy following 12 weeks 
of combined cycling and resistance exercise (Allison et al., 2019; Herrstedt et al., 2019).  
Moreover, several studies have investigated the impact of physical exercise on KYNA levels 
in plasma. Different types of physical exercise, such as marathon race, half marathon race, 150 
km road cycling, and 30 or 45 minutes cycling increase the levels of KYNA in plasma of 
healthy subjects (Lewis et al., 2010; Schlittler et al., 2016; Joisten et al., 2020), as well as 30 
minutes cycling in type 2 diabetes subjects (Mudry et al., 2016). On the contrary, 100 drop 
jumps did not affect plasma KYNA levels in healthy subjects (Schlittler et al., 2016). No effect 
on KYNA was neither seen when elderly at risk of dementia performed 10 weeks program of 
physical training (a mixed program of endurance, balance, coordination, strength exercises) 
(Küster et al., 2017), or in mild to moderate depressed patients following 12 weeks of light, 
moderate or vigorous exercise (Millischer et al., 2017), or in elderly and patients with 
gastroesophageal junction cancer receiving chemotherapy following 12 weeks of combined 
cycling and resistance exercise (Allison et al., 2019; Herrstedt et al., 2019).  
Some studies have also investigated how plasma levels of QUIN are affected by physical 
exercise and both increase and no change have been observed. In healthy subjects, levels of 
plasma QUIN were increased from a marathon race (42.2 km) (Lewis et al., 2010), 150 km of 
road cycling time trial (Schlittler et al., 2016), or 45 minutes of cycling (Joisten et al., 2020). 
In healthy subjects, plasma QUIN levels did not change following 100 drop jumps (Schlittler 
et al., 2016), or following resistance exercise (Joisten et al., 2020). No changes were neither 
seen in the elderly and elderly at risk of dementia following  12 weeks of combined cycling 
and resistance exercise, and 10 weeks program of physical training (a mixed program of 
endurance, balance, coordination, strength exercises) respectively (Küster et al., 2017; Allison 
et al., 2019).  
The effects of physical exercise on neuropsychiatric disorders are of interest. Those effects 
seem to be linked to immune markers (Phillips & Fahimi, 2018; Ignácio et al., 2019), however, 
an exact mechanistic explanation of the relation between physical activity, immune markers, 
and clinical effects are missing. One study in rodents suggests a putative mechanism for this 
effect. Thus, exercise stimulates skeletal muscle expression of peroxisome proliferator-
activated receptor-gamma coactivator 1-alpha (PGC-1a1) and increases the expression of the 
four KAT enzymes, that transform kynurenine into KYNA (Agudelo et al., 2014). This may 
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be attributed to lower levels of pro-inflammatory cytokines in the hippocampus of the same 
mice (Agudelo et al., 2014). Another study also reported increased gene and protein expression 
of KAT I, II, III, and IV enzymes in the muscles of subjects after endurance training, 150 km 
road cycling (Schlittler et al., 2016). One recent study showed that mice exposed to chronic 
mild stress had increased kynurenine and decreased KYNA in plasma (Fang et al., 2021). 
Interestingly, when those mice were treated with caffeine, gene expression of KAT I in skeletal 
muscles was upregulated, and PGC-1a1 was upregulated too. Thus, this study suggests that 
caffeine protects mice from stress-induced depression by upregulating PGC-1a1, which 
induces KAT 1 and hence restores kynurenine levels in the skeletal muscle (Fang et al., 2021). 
This might lead to a clearance of kynurenine from the plasma and thereby less kynurenine is 
transported through the BBB into the brain.   
Moreover, supporting evidence of changes in immune markers has also been seen in healthy 
subjects (Gonçalves et al., 2020). Thus,  pro-inflammatory cytokines, such as IL–12, IL–17, 
IL–18, TNF–α, INF–γ, chemokine monocyte chemotactic protein-1 (MCP–1), and anti-
inflammatory cytokines such as IL–2R, IL–4, IL–5, IL–10, IL–13 were increased after a first 
soccer game in the plasma of female soccer players but were not affected after the second game 
separated by 72 hours recovery (Andersson et al., 2010). Nevertheless, the central modulation 
of immune markers following exercise is limited. One study reported minimal changes in 
concentrations of 17 of the 174 cytokines tested in CSF of healthy volunteers after an acute 
bout of intense aerobic exercise (Schön et al., 2019). Another study reported no changes of IL-
6 in the CSF of healthy controls, while in plasma IL-6 was increased after cycle ergometer 
exercise (Steensberg et al., 2006).  
Effects seen from exercise are a result of communication between body and brain (Cooper et 
al., 2018). However, in biomarker research, it's unclear how exercise affects immune markers 
and kynurenine pathway metabolites centrally, and to what extent this is reflected by changes 








2 RESEARCH AIMS 
 
Overall aim of the thesis   
Develop a sensitive method for measuring kynurenine pathway metabolites in human CSF and 
plasma in order to investigate them as potential future biomarkers for psychiatric disorders and 
for understanding how physical exercise affects them. 
Specific aims 
1. Develop and validate a biochemical method for simultaneous quantification of 
kynurenine metabolites in human CSF and plasma that is highly sensitive, robust, 
and reliable. 
 
2. Confirm previous observations of abnormal PIC/QUIN ratio in the CSF of suicide 
attempters compared to healthy controls in a small well-characterized cohort. 
 
3. Analyze kynurenine metabolites in the CSF of patients with bipolar disorder. 
 
4. Investigate if concentrations of kynurenine metabolites are linked to a history of 
suicidal behavior in patients with bipolar disorder.  
 
5. Investigate possible associations between kynurenine metabolites in the CSF of 
patients with bipolar disorder with their pharmacological treatment and also with 
symptoms.  
 
6. Investigate whether ACMSD gene variants affect PIC, QUIN, or the PIC/QUIN 
ratio in patients with bipolar disorder, without or with suicidal behavior. 
 
7. Investigate how SIE affects kynurenine metabolites in plasma of healthy subjects 
of different age groups.  
 
8. Investigate how aerobic exercise affects kynurenine metabolites and immune 














3 MATERIALS AND METHODS 
3.1 Ethical considerations  
Human studies are approved by Regional Ethical Review Boards in Lund, Sweden for Paper I 
(Dnr 150/2018); in Stockholm, Sweden for Paper II and IV (Dnr 2014/1201-31/1 and Dnr 
2005/554-31/3) and in Kaunas, Lithuania for Paper III (BE 2-5).  
All the studies were carried out following “The code of ethics of the world medical association” 
(Declaration of Helsinki) for experiments including human subjects. Every participant in the 
studies received verbal and written information about the research project and provided oral 
and written informed consent to participate in the study.  
All CSF and plasma samples used in these studies are coded with unique barcodes. All personal 
data of the participants are coded, encrypted, and separately stored. Transfer of information 
about subjects between researchers is carried strictly following the requirements and conditions 
in The General Data Protection Regulation (GDPR). 
 
3.2  Human subjects  
3.2.1 Stability cohort  
Ten patients with multiple sclerosis (MS) at the Karolinska University Hospital's MS outpatient 
clinic were asked to participate in the study between December 2017 and March 2019. 
Including criteria were: 1. no significant somatic or psychiatric diagnoses other than MS; 2. no 
psychiatric or psychotropic drugs; 3. being between the ages of 18 and 55 years old. Six 
subjects provided both CSF and blood samples and the other four subjects only CSF. 
Four healthy volunteers enrolled in the Karolinska Schizophrenia Project (KaSP) in 2019 
provided blood samples for the study. 
 
3.2.2 Suicide cohort  
Between 2009 and 2012, thirteen patients were admitted to Lund University Hospital after 
attempting suicide. A psychiatrist diagnosed all patients using the DSM IV soon after the 
suicide attempt. The doctor made his diagnosis a few days after the suicide attempt, after a long 
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structured interview that lasted about two hours using the Comprehensive Psychiatric Rating 
Scale (Åsberg & Schalling, 1979) and the Structured Clinical Interview for DSM Disorders 
(SCID I and II).  
The inclusion criteria were that the subjects had performed a suicide attempt with the aim to 
end their life. A suicide attempt was defined as “situations in which a person has performed 
an actually or seemingly life-threatening behavior with the of jeopardizing his/her life” (Beck 
et al., 1972). Subjects had a diagnose and suicidality was a cross-diagnostic phenomenon 
(Diagnostic and Statistical Manual of Mental Disorders [DSM] V).  
Before being part of the study, the medical history of the subjects was investigated. To identify 
any participants that might have infections, all subject´s temperature was measured and the 
blood for erythrocyte sedimentation rate, C-reactive protein, and white blood cell count was 
screened.  
When subjects were enrolled in the study, eleven of the thirteen patients were on medical 
treatment, 8 subjects were using antidepressants, 6 subjects were taking painkillers, 6 subjects 
were taking sleep aids, 5 subjects were taking antipsychotics, 4 subjects were taking anxiolytics 
and 3 of them were taking mood stabilizers.  
 
3.2.3 St. Göran Bipolar Project 
The St. Göran Bipolar Project (SBP) is a prospective and longitudinal study of euthymic 
patients with bipolar disorder. Patients were enrolled from the bipolar unit at the Northern 
Stockholm Psychiatric Clinic, Stockholm, Sweden. All patients met the criteria of the DSM-
IV for being diagnosed with Bipolar Disorder type I, II, cyclothymic disorder, or bipolar 
disorder not otherwise specified. Moreover, the Montgomery - Åsberg Depression Rating Scale 
(MADRS) (Montgomery & Asberg, 1979) and the Young Mania Rating Scale (YMRS) 
(Young et al., 1978) were used to assessing the extent of ongoing depressive and manic 






3.2.4 Healthy subjects  
Paper I  
Thirteen healthy controls were randomly selected by the Swedish population registry to 
become part of the study. Afterward, they were contacted by phone. They were all somatically 
healthy, and they did not suffer from any previous or ongoing psychiatric condition or 
substance abuse. Two subjects were taking pain killers, one subject was taking oral 
contraceptives and two of them were taking nonprescription allergy medications. 
Paper II 
Eighty healthy controls were randomly selected by Statistics Sweden (SBC, http://www.scb.se) 
registry to become part of the study. Afterward, they were contacted by mail. Subjects with 
neurological conditions, dementia, pregnancy, untreated endocrine disorders, and chronic 
systemic autoimmune disorders, except persons with controlled asthma and allergies, as well 
as any current psychiatric disorder including a family history of schizophrenia or bipolar 
disorder in first-degree relatives personality disorder, drug or alcohol abuse (based on DUDIT, 
AUDIT and serum levels of carbohydrate- deficient transferrin) were not included in the study. 
Mini-International Neuropsychiatric Interview (MINI) (Sheehan et al., 1998) was used to for 
psychiatric disorders screening.  
Paper III 
Twenty recreationally active healthy volunteers, all males, participated in the study. Subjects 
were not following structured physical activity. Subjects were allocated into 2 subgroups, 
young and old.  
Paper IV  
Healthy subjects were recruited from student campuses by advertising. In order to be part of 
the study subjects should be not younger than 18 years old. Subjects that wanted to be part of 
the study were contacted by phone and afterward they were scheduled for an inclusion 
assessment with a consultant psychiatrist and their medical history was investigated. Subjects 
with psychiatric disorder, inflammatory, infectious, or autoimmune conditions could not be 




3.3 CSF and plasma  
3.3.1 Lumbar puncture  
Subjects in papers I, II, and IV went through a lumbar puncture. After a night of bed rest and 
fasting, a standardized CSF sampling occurred between 8.00 - 11.00 a.m. for subjects in paper 
I; 9.00 - 10.00 a.m. for subjects in paper II and 7.30 - 9.00 a.m. for subjects in paper IV. A non-
cutting spinal needle was inserted between the vertebral interspaces L3/L4 or L4/L5 to collect 
CSF. To prevent gradient effects, the CSF sample was gently inverted and divided into 1.0 -
1.6 mL aliquots that were stored at -80°C until analysis (except for the samples that were used 
for stability testing).  
 
3.3.2  Plasma isolation  
Peripheral blood from subjects in papers III and IV was obtained. Blood collection was done 
using tubes containing ethylenediaminetetraacetic acid (EDTA) by using the standard 
venipuncture techniques. Blood was drawn in the morning between 7.30 and 9.00 a.m. for 
subjects in paper IV, after a full night of bed rest and fasting since midnight. Plasma was 
isolated by centrifugation at 2900 rpm for 15 minutes within 1 hour of blood collection and 
stored at -80°C pending analysis.  
 
3.4 UPLC–MS/MS – kynurenine metabolites analysis in CSF and 
plasma  
3.4.1 Chemicals and reagent  
Tryptophan, L-kynurenine, KYNA, 3-HK, XA, 3-HANA, pyridine-2,3-dicarboxylic acid 
(QUIN), PIC, NA, and NAA used for preparing the normal standard mixture for UPLC-
MS/MS analysis were all purchased from Sigma-Aldrich (MO, USA).  
Tryptophan-d3, L-kynurenine-d4, QUIN-d3, [13C6], NAA, [13C6]NA, XA-d4, 3-HK-d3, and 
3HANA-d3 used for preparing the internal standard (IS) mixture were purchased from Toronto 
Research Chemicals, Canada (Toronto, Canada). Two IS, KYNA-d5 and PIC-d4 were 
purchased from C/D/N Isotopes Inc. (Quebec, Canada).  
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Methanol and formic acid 99% used for plasma preparations were LC-MS grade and they were 
purchased from Chromasolve, Honeywell, VWR International AB, (Stockholm, Sweden). 
Ammonia (32%) and ZnSO4 used also for plasma preparations, were purchased from VWR 
and Sigma-Aldrich (MO, USA) respectively.  
  
3.4.2 Standard solutions  
Stock solutions of kynurenine, KYNA, 3-HK, XA, 3-HANA, QUIN, PIC, NA, and NAA at 
100 μM and tryptophan in 1000 μM in water UPLC grade were prepared and then stored at    -
20°C. Afterward, a mixture of all stock solutions was prepared, generating a final solution of 
100 μM for tryptophan and 10 μM for the other compounds. The second batch prepared had a 
final solution of 8.3 µM for nine of the compounds and ten times higher for tryptophan, 83 µM. 
The standard mix was aliquoted in volumes of 200 μL and stored in -80°C. Before each 
experiment, one aliquot of the standard mix was thawed and serial dilutions in water UPLC 
grade were prepared.  
Stock solutions of l-kynurenine-d4, KYNA-d5, QUIN-d3, [13C6], PIC-d4, NAA, [13C6]NA, XA-
d4, 3-HK-d3 and 3HANA-d3  at 50 μM and tryptophan in 500 μM in water UPLC grade were 
prepared and then stored at -20°C. Afterward, a mixture of all stock solutions was prepared, 
generating a final solution of 5 μM with an exception of tryptophan-d3, which had the final 
concentration of 50 μM. The second batch of IS had a final concentration of 4.1 µM for nine 
of the compounds and 41 µM tryptophan-d3. The IS mix was aliquoted in volumes of 350 μL 
and stored in -80°C.  
 
3.4.3 Analysis  
The UPLC–MS/MS system used a Xevo TQ–XS triple quadrupole mass spectrometer (Waters, 
Manchester, UK) with a Z-spray electrospray interface and Waters Acquity UPLC I-Class FTN 
system (Waters, MA, USA). Data processing and acquisition was performed using the software 
package MassLynx v 4.1 SCN943 SCN979 (© 2016 Waters Inc.). The UPLC conditions were 
as follow: separation performed on an Acquity UPLC® HSS T3 column (1.8 μm, 2.1×150 mm) 
from (Waters, part number: 186003540) column temperature 50°C; guard column (Waters, 
Vanguard HSS T3 1.8 μm, 2.1×50 mm column, part number: 186003976) was installed to 
retain contaminants from the mobile phase. The mobile phase consisted as follow: (A) 0.6% 
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formic acid in water (UPLC grade) and (B) was 0.6% formic acid in methanol (UPLC grade). 
The flow rate was 0.3 mL/min and the run time for each sample was 13.0 minutes. The MS 
was operated in electrospray-positive multiple reaction monitoring (MRM) mode. The 
capillary voltage was set to +3.0 kV. The source temperature was 150°C, the cone gas flow 
was 150 L/h and the desolvation gas flow rate was 1000 L/H. The desolvation temperature was 
650°C and detector gain 1 was used. The m/z for the MRM transitions of each individual 
analyte, along with optimal cone voltages and collision energies were determined by manual 
tuning using the instrument’s built-in fluidics system (MassLynx v 4.1 software) (Table 1). A 
10 μL/min flow of 100 ng/mL tuning solution was introduced to the mass spectrometer. This 
was combined with an LC flow of 0.2 mL/min and a composition of 20/80 mobile phase A / 
mobile phase B. The MRM transition providing the highest sensitivity was chosen as 
quantification trace for all compounds, except for tryptophan (and kynurenine too in case of 
plasma) where the second most intense transition was chosen. 13C isotopes were selected to 
reduce overall signal intensity. This provided better linearity of the response over the 
calibration range, since the concentration of tryptophan in CSF samples (as well as kynurenine 
in plasma samples) are significantly higher than for the other analytes in this method. The dwell 
times for the MRM channels were automatically calculated by the software, giving a desired 
number of 15–20 data points across the chromatographic peak. Table 1 shows a summary of 
the precursor/product transitions for all compounds and their respective IS. The autosampler 






















Tryptophan 206.1 118 20 24 
  146** 20 16 
Kynurenine 209.1 94 20 12 
  146 20 18 
KYNA 190.1 116 30 28 
  144 30 17 
QUIN 168.1 78 20 18 
  124 20 10 
PIC  123.9 78* 30 16 
  96 30 16 
NAA 123 78 25 16 
  80* 25 16 
3HK 225.2 110.1 14 16 
  162.1 14 16 
NA 123.9 80* 25 16 
  96 25 16 
XA 206.1 160.0 25 16 
  132.0 25 30 
3HANA 154 108* 20 18 
  136 20 10 
Tryptophan-d3 208.1 118.8 40 26 
Kynurenine-d4 213.2 94 30 15 
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KYNA-d5 195 121 28 26 
QUIN-d3  171 81 20 18 
PIC-d4 128 82 4 17 
NAA [13C6] 129.1 101 20 16 
3HK-d3 228.2 163 14 16 
NIC [13C6] 130.1 85.2 32 20 
XA-d4 210.1 192 25 10 
3HANA-d3 157 83 24 24 
Table 1. Transitions and mass spectrometry parameters for all the compounds and their internal 
standards. 
*quantifying ion; ** MS transition using 13C isotopes and product ion with low response were selected 
to reduce the overall signal intensity. 
 
3.4.4 Methods validation  
The methods were validated for calibration curve linearity, lower limit of quantification 
(LLOQ), selectivity, specificity, accuracy, precision, matrix effects and stability following the 
guidelines of bioanalytical method validation from European Medicines Agency (EMA) and 
the US Department of Health and Human Services Food and Drug Administration (FDA). The 
calibration curve linearity was tested using a standard mix of all metabolites diluted in water. 
The concentrations  for CSF analysis ranged from 0.1 to 250 nM (for tryptophan concentrations 
ranged from 0.1 to 25 μM) and for plasma analysis concentrations ranged from 0.006 and 8.3 
µM (for tryptophan the concentrations ranged from 0.06 to 83 µM). All the standard mix 
concentrations, human CSF and plasma sample were analyzed in duplicates. The standard 
curve was calculated by 1/X-weighted least squares linear regression of standard curve 
calibrator concentrations and the peak area ratios of analyte to IS. In order to estimate the limit 
of detection (LOD) and the LLOQ,  a signal-to-noise (S/N) ratio of 3 and S/N ratio of 10, 
respectively, was used. The guidelines recommend accuracy and precision variations are ±15% 
(LLOQ: ±20%) of nominal concentrations for chromatographic assays. In this thesis, the 
selectivity for all metabolites was investigated by comparing chromatograms of CSF or plasma 
obtained from six different human samples spiked with a mixture of ten metabolites and IS to 
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make sure that it was free of interference at the retention time of the compounds. Spiked CSF 
and plasma in two different concentrations each were used in order to test the accuracy and 
precision of the assay (see Table 2). The assay accuracy is presented as percentage recovery 
and is calculated as follows: (100 × [measured Cspiked - Cnonspiked / Cspiked]). The assay precision 
is expressed as percent relative standard deviation and calculated as follows: STDEV [Data 
Range]/AVERAGE [Data Range] *100). Intra-assay accuracy and precision results come from 
six analyses of the same sample within the same experiment. Inter-assay accuracy and precision 
results come from three different experiments running over 2 days. The matrix effect was 
calculated from the area of the IS in pooled CSF or plasma human sample (n = 6) in relation to 
the peak area of a prepared sample of pure water (n = 6), prepared exactly as the human sample, 
as (Area [sample] / Area [water] - 1) *100%. The matrix effect should be reproducible and 
consistent. 
Compound 
Concentrations used to spike  
CSF Plasma  
Low (A) High (B) Low (A) High (B) 
Tryptophan 1.5 μM  15 μM    9 µM   40 µM 
Kynurenine 50 nM 500 nM 1.5 µM     3 µM 
KYNA   2 nM  20 nM  50 nM 500 nM 
3-HK   5 nM  50 nM  50 nM 500 nM 
XA   2 nM   20 nM  15 nM 150 nM 
3-HANA   2 nM   20 nM  40 nM 400 nM 
QUIN 20 nM 200 nM 300 nM     3 µM 
PIC 20 nM 200 nM  70 nM 700 nM 
NA   2 nM   20 nM    2 nM  20 nM 
NAA 10 nM 100 nM 150 nM 1.5 µM 
Table 2. Concentrations used to spike the CSF and plasma in order to investigate the accuracy 




3.4.5 Sample preparation  
CSF  
30 μL of human CSF sample, standard mix, or Quality Control sample was mixed with 30 μL 
of IS working solution for 15 seconds. The IS working solution was prepared by diluting of IS 
mix in a ratio of 1:5 with 5% formic acid in water. The mixing was done in LC-MS Certified 
Clear Glass 12 × 32 mm vials (Waters, PN: 186005662CV). Samples were transferred to the 
autosampler (5°C) and a volume of 3 μL was injected into the UPLC-MS/MS system.  
Plasma 
30 μL of human plasma sample, standard mix, or Quality Control sample was mixed with 30 
μL of IS 0.5 μM in 10% ammonia for 15 seconds. In addition,  60 μL of 200 nM ZnSO4 (5°C) 
was added and then mixed for 15 seconds. This was followed by adding 30 μL of methanol 
(5°C) and mixed for 15 seconds. Afterward, the mixture was centrifuged at 2841×g for 10 
minutes at room temperature. 30 μL of the supernatant obtained after the centrifugation was 
mixed with 30 μL of formic acid 5% in LC-MS Certified Clear Glass 12×32 mm vials (Waters, 
product no. 186005662CV). Samples were transferred to an autosampler (5°C) and a volume 
of 1.5 μL was injected into the UPLC-MS/MS system 
 
3.4.6 Stability test  
Kynurenine metabolites, both in CSF and plasma human samples, were investigated how stable 
they are when they have been held at room temperature for varying amounts of time and when 
undergoing multiple freeze-thaw. The storage times at room temperature and the number of 
freeze-thaw cycles were chosen to cover normal sample preparation, analysis, and storage 
conditions. 
Precisely, CSF and plasma kynurenine metabolites stability before and after the first freezing 
was tested by analyzing samples directly after lumbar puncture and blood drawing (followed 
by plasma isolation), after 24 h at room temperature (before any freezing), and then again after 
one freeze cycle. Further, were tested the stability of kynurenines for 4 freeze-thaw cycles 
stored at -80°C.  Moreover, CSF and plasma kynurenine metabolites stability were also tested 
for 30 minutes, 1, 2, 3, and 4 hours stored at room temperature.  
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The stability of the metabolites at a specific time or freeze-thaw cycle is expressed as the 
average percentage of the six or four individual CSF / plasma ± standard deviation (SD) in 
relation to the baseline mean concentration of the correspondent metabolite. 
 
3.5 HPLC – analysis of neurotransmitters  
3.5.1 Chemicals and reagents 
The standard γ-aminobutyric acid (GABA) and amino acid mix solution containing glutamate 
and serine were purchased from Sigma-Aldrich (MO, USA).  
Sodium acetate, tetrahydrofuran, and methanol 99% LC-MS grade used for preparing the 
mobile phases were purchased from Sigma-Aldrich (MO, USA) and Chromasolve, Honeywell, 
VWR International AB, (Stockholm, Sweden) respectively.  
O-phthaldialdehyde, 2-mercaptoethanol, boric acid, NaOH, ethanol 99.5%, used for CSF 
preparations to analyze GABA, glutamate, and serine were purchased from Sigma-Aldrich 
(MO, USA).  
 
3.5.2 Standard solutions  
Stock solution for GABA was prepared at 100 µM in HCl 0.1M, glutamate and serine were 
prepared at 12.5 µM. All compounds were mixed generating a final solution of 10 µM for 
GABA and 20 µM for glutamate and serine in MilliQ water.   
 
3.5.3 Analysis  
HPLC was used for analyses of glutamate, GABA, and serine. HPLC was equipped with a 
gradient pump (Spectra System P4000, Waltham, MA, USA), ), a degasser (Spectra System 
SCM 400), a Luna 100 C18(2) column (50 × 2 mm i.d., 5 μm particle size, Phenomenex, 
Torrance, CA, USA) and fluorescence detection (Jasco FP-920, Japan). The excitation and 
emission wavelength of 495 and 344 nm were used for analyses of glutamate, GABA, and 
serine, respectively.  
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The flow rate was 0.5 mL/min and 20 μL of CSF sample was injected manually into the HPLC 
system. Two mobile phases used consisted of (I) 0.04 M sodium acetate buffer with a pH=6.95, 
with 2.5% (v/v) methanol and 2.5% (v/v) tetrahydrofuran (II) methanol. HPLC system started 
with 100% mobile phase (I), the gradient changed to 70% mobile phase (I) and 30% mobile 
phase (II) from time 0 to 11 minutes, then the gradient changed to 10% mobile phase (I) and 
90% mobile phase (II) from 11 to 13 minutes, at the 14th minute the gradient changed to 100% 
mobile phase (I) and conditions did not change until the next injection. The retention times 
were glutamate 2.8 minutes, serine 5.4 minutes and GABA 11.9 minutes. Signals from the 
detector were sent to the computer, where they were analyzed using the software Datalys Azur 
Software version 4.6.0.0 (Grenoble, France).  
 
3.5.4 CSF sample preparation  
In order to analyze glutamate, GABA, and serine, CSF human samples were mixed with O-
phthaldialdehyde / 2-mercaptoethanol (OPA / 2-MCE) reagent for 60 seconds. The reagent was 
prepared by solving 27 mg OPA in 0.5 mL ethanol (99.5%) and then mixing it with 4.5 mL 
borate buffer (0.4 M boric acid adjusted pH 10.4 with NaOH) and 20 μL 2-MCE.  
 
3.6 Proximity extension assay - immune markers analysis 
Proseek® Multiplex Inflammation I96×96 proximity extension assay (PEA) was used to 
determine immune markers in CSF and plasma. PEA uses a proximity extension technology to 
enable a high throughput multiplex proteomic immunoassay (Olink, Uppsala, Sweden) 
(Assarsson et al., 2014). The panel consisted of cytokines, chemokines, and a selection of other 
immune-related proteins. In total 92 immune markers. The assay uses epitope-specific binding 
and hybridization of a set of paired antibodies linked to oligonucleotide probes, which can then 
be amplified using a quantitative polymerase chain reaction to quantify relative protein 
concentrations in terms of log base-two normalized protein expression (NPX) values. 
 
3.7 Genotyping  
Tag single nucleotide polymorphisms (SNPs) for ACMSD (± 20kB) were chosen using Tagger 
(HapMap analysis panel: CEU, r2 threshold = 0.8). SNP genotyping (rs10176573, rs10496731, 
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rs10928521, rs11897287, rs1519304, rs16830596, rs16831005, rs16831432, rs1954874, 
rs2121337, rs4953936, rs6430484, rs6430538, rs6712534, rs6714498, rs6722883, rs7604436) 
were performed using 5´nuclease assay chemistry with custom competitive allele specific PCR 
(KASP) technology probes (He et al., 2014) at the Genomics Core Facility at the University of 
Gothenburg, Sweden.     
 
3.8 Exercise protocols  
3.8.1 Sprint interval exercise  
The exercise bout consisted of 1 sprint interval exercise (SIE) session. The SIE began with an 
8 minutes warm-up session cycling at a power (W) equal to the individual’s body mass (kg). 
This is followed by 30-seconds all-out cycling bout at 0.7 Nm/kg body weight repeated 6 times 
and 4-minutes passive recovery periods in between (Place et al., 2015). Five mL blood sample 
was collected before SIE (baseline), 1 hour, and 24 hours after SIE. Study participants were 
not allowed to eat for at least 2 hours before the SIE.  
 
3.8.2 Aerobic training  
Study participants were divided into 2 sub-groups based on their physical exercise habits. To 
evaluate the exercise habits weekly frequency and intensity of exercise of the last 6 months 
was considered. The intensity of the exercise was evaluated using The Borg Rating of 
Perceived Exertion (RPE scale), which ranges from 6 (nothing at all) to 20 (maximum) (Borg, 
1982). RPE score of 12–13 represent moderate intensity, RPE score of 14–17 represent 
vigorous and RPE score ≥18 represent near-maximal to maximal intensity (Garber et al., 2011). 
Study participants that for at least 3 times a week run for up to 60 min, performed high-intensity 
interval training or resistance training, were allocated to the acute exercise group. Acute 
exercise 4 consecutive days of running. Study participants allocated in the acute group had to 
run 4 consecutive days. The first and the third day they were instructed to do a 30-minute high-
intensity interval-training  i.e. 10 intervals of one-minute high intensity run (Borg RPE 18–19) 
followed by two minutes of low intensity run (Borg RPE (9–11). On second and fourth day, 
study participants were instructed to run for at least 60 minutes at a vigorous pace (RPE average 
14–16). Study participants that exercised at least twice a week, taking power walking or slow 
jogging were allocated to the training exercise group. This included a minimum of 30 min 
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running at a vigorous intensity (Borg RPE 14–16) three times weekly for 4 weeks, i.e. a total 
of 12 sessions.  
Subjects  that participated in the study were instructed to refrain from any physical exercise for 
seven days prior to baseline sampling, with the goal of limiting the acute effects of recent 
exercise on biomarker levels. Before starting the exercise intervention, baseline blood and CSF 
samples were taken, and follow-up exercise samples were taken the day after the last exercise 
session.  
 
3.9 Data analysis  
Statistical analyses were performed using: 
o GraphPad Prism 8 and 9 for Mac (GraphPad, La Jolla, Ca, USA) – Paper I, II, III, IV 
o Statistical Package for the Social Sciences 20.0 and 25 for Mac (SPSS, IL, USA) – 
Paper I and II respectively  
o R-programming language, version R-3.2.3 (Vienna, Austria) – Paper IV 
Paper I  
The nonparametric two-tailed Mann–Whitney U-test was used to compare age, BMI and 
concentrations kynurenine metabolites, between healthy controls and suicide attempters. The 
nonparametrical one-tailed Mann–Whitney U-test was used when analysis was hypothesis 
driven, as in case of CSF levels of QUIN, PIC as well as the ratios kynurenine/tryptophan, 
PIC/QUIN. Data are expressed as mean ± SD. Statistical significance was considered when P 
< 0.05. 
Paper II  
The normality distribution was determined using D ́Agostino & Pearson normality tests. 
Comparisons between healthy controls and patients with bipolar disorder were performed using 
Chi-square tests, Mann–Whitney U -tests, linear mixed or logistic regression model. Post-hoc 
Bonferroni correction followed multiple comparisons of genetic data analysis. All reported P-
values, except for CSF PIC levels, are two-tailed. Data are expressed as Median ± Inter Quartile 




Paper III  
The nonparametric two-tailed Mann–Whitney U-test was used to compare differences between 
young and old metabolite levels at baseline (data presented as mean ± SEM). Kruskal-Wallis 
followed by post-hoc Dunn’s test was used to analyze how SIE affected the metabolites and 
each time after SIE was compared with the baseline. Method validation data are presented as 
mean ± SD. Statistical significance was considered when P < 0.05. 
Paper IV   
The multi-variable linear regression models adjusting for sex and was used for data analysis. 
The paired Student t-test was used to compare the differences in kynurenine metabolites and 
immune markers between baseline and follow-up. A multi-variable linear regression model 
adjusting for sex and age and along with curated markers of sample handling, chemokine (C–
C motif) ligand 19 (CCL19) (CSF), and axin-1 (plasma) was used to control for potential effects 
of pre-analytical variability relating to potential differences in sample handling. Correlations 
were performed using the false discovery rate (FDR) model with a significance cutoff positive 
false discovery rate PFDR<5. After correcting for multiple testing, statistical significance was 



















4 RESULTS AND DISCUSSION  
 
4.1 UPLC–MS/MS method validation (Paper I, III) 
The UPLC-MS/MS method for analyzing the kynurenine metabolites in human CSF and 
plasma was validated following the guidelines for bioanalytical method validation from US 
FDA (https://www.fda.gov/files/drugs/published/Bioanalytical-Method-Validation-Guidance-
for-Industry.pdf) and EMA (https://www.ema.europa.eu/en/documents/scientific-
guideline/guideline-bioanalytical-method-validation_en.pdf). The main objective for both 
guidelines is to ensure highly reliable data. The guidelines do not only highlight the importance 
of the method´s sensitivity, accuracy, and precision, but they also stress the importance of 
understanding the biological variability in different matrixes (plasma, serum, cerebrospinal 
fluid, etc.), as well as the stability of the analyte during different handling conditions. In the 
following sections, we present data from different test validations on all these parameters. 
 
4.1.1 Calibration curve linearity  
The calibration curve should be tested within the concentration range found in the unique 
samples for which the system is being established for. The calibration curves must be 
continuous and repeatable. 
CSF 
We used a calibrator mixture of all metabolites to test the linearity. In this mixture, the 
concentrations of tryptophan were from 0.1 to 25 μM and the concentrations of other 
metabolites were from 0.1 to 250 nM. Within the concentration ranges tested, they all showed 
good linearity (see Table 3). 
Plasma  
A calibrator mixture of all metabolites was used also to test the plasma method calibration 
curve linearity. In this case, the concentrations of tryptophan were from 0.06 to 83 μM and of 
nine other metabolites from 0.006 to 8.3 µM. Within the concentration ranges tested, all ten 




4.1.2 Lower limit of quantification  
The lower limit of quantification (LLOQ) represents the lowest concentration of the metabolite 
that can be quantified in a reliable way, having precision and accuracy that is acceptable. The 
LLOQ defines the sensitivity of the method. The limit of detection (LOD) is the lowest 
concentration of the metabolite which is possible to be detected and distinguished from the 
background noise. A signal-to-noise (S/N) is a unitless parameter that determines the 
relationship between an analytical signal and the mean noise level for a given sample.  An S/N 
ratio of 10 was used to estimate the LLOQ. Here we also present the LOD, which is estimated 
by S/N of 3.  
The LLOQ values for all metabolites in CSF and plasma are presented in Table 3 and Table 4, 
respectively. Of note, 3-HANA, XA and NA could be detected in less than 15% of the CSF 
samples analyzed, and NA could be detected in less than 30% of plasma samples analyzed, 
therefore they were not included in further analysis.  
 
4.1.3 Selectivity and specificity  
During the method validation, it is important to ensure that the method has the appropriate 
selectivity.  The metabolite measured should be the intended one, without any interference with 
other compounds such as degradation products formed during sample preparation, structurally 
similar metabolites, or administrated drugs. The specificity of the current method included 
chromatographically separation of NA from PIC. These two metabolites have the same 
chemical formula C6H5NO2, but not the same chemical structure, they are isomers. The 
carboxyl group (-COOH) in PIC’s chemical structure is at the second position (Figure 2e), 
while in NA it is at the third position (Figure 2f).   
As suggested by both EMA and US FDA guidelines, selectivity was tested using CSF and 
plasma from at least six individual subjects. These subjects represented both healthy subjects 
and patients with MS. 
We tested the selectivity for all ten metabolites in plasma and CSF by comparing 
chromatograms from blank CSF/plasma with CSF/plasma spiked with a mixture of 10 
metabolites to make sure that no interference is present at the respective retention time of each 
metabolite. Chromatograms of the metabolites were found to be free from any interference in 
both CSF and plasma. Importantly, PIC and NA showed a clear chromatographic separation in 




Figure 2. Chromatographically separation of PIC and NA in human CSF. 
a) standard solution of 1 nM, b) CSF c) CSF spiked with 20 nM PIC and 2 nM NA, d) CSF spiked with 20 nM 




Figure 3. Chromatograms of kynurenines free from any interference and chromatographically separation 
of PIC and NA in human plasma. 
a) Chromatograms of NAA, PIC, NA, QUIN, 3-HK, kynurenine, 3-HANA, tryptophan, XA, KYNA in human 
plasma, their chemical structures and their respective retention times; Chromatograms showing the separation of 
PIC from NA, b) in standard solution (6nM), c) in human plasma d) in spiked plasma showing that the separation 
is still present at higher concentration (1μM). ES+, TIC, MRM belong to PIC.  
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4.1.4 Accuracy and precision  
The accuracy of the method presents the closeness of the determined concentration to the 
nominal concentration. The accuracy is present in percentage (%). The precision is the 
closeness of repeated measures of the metabolite. The precision is presented in relative standard 
deviation in percentage (RSD%). The method should be validated for inter-assay (between run) 
as well as intra-assay (within run) accuracy and precision. We tested the intra-assay accuracy 
and precision for six repeated measurements within one single assay and the inter-assay 
accuracy and precision for three different assays analyzed on two different days. We accepted 
variation less than 15% of the nominal value in line with the criteria of the US FDA and EMA 
guidelines.  
CSF 
Two different concentrations of spiked human CSF were used to assess accuracy and precision, 
and they were chosen to cover the range of concentrations found in human CSF. Nine of 
kynurenine metabolites showed satisfactory intra-assay accuracy with minor variations, 
ranging between 85% and 112%. All ten intra-assay precision values were satisfactory, 
between 1 and 9 RSD%. The inter-assay accuracy values were also in the acceptable range, 
between 86% and 113%. Furthermore, all inter-assay precision values were satisfactory, from 
1 to 14 RSD%. The only metabolite with unsatisfactory variation in both intra- and inter-assay 
accuracy was 3-HANA, 134% and 140% of target tested, respectively, for the samples spiked 
with low concentration (see Table 3).  
Plasma  
The same procedure was followed also for plasma, and in this case, two different concentrations 
for spiking were chosen to cover the range of concentrations found in plasma. For all 
metabolites, the intra-assay accuracy and precision were satisfactory, ranging from 87% to 
110% and 0.9 to 4.4 RSD%, respectively. The estimated inter-assay accuracy values for nine 
metabolites were between 85.2% and 114.8%, while the inter-assay precision values for all ten 
metabolites were between 1 and 14 RSD%. 3-HANA was the only metabolite that did not meet 




4.1.5 Matrix effect  
According to the EMA or US FDA bioanalytical method validation guidelines, the matrix 
effect is defined as “a direct or indirect alteration or interference in response because of the 
presence of unintended analytes (for analysis) or other interfering substances in the sample”. 
The matrix effects on kynurenine metabolites in CSF and plasma were determined by 
calculating the ratio of the IS peak area mean of six CSF or plasma samples, to the IS peak area 
mean of the blank and were expressed in percentage. Matrix effects for CSF and plasma are 
















Intra-assay (n=6 during 20 h in +5°C) Inter-assay (n=3) 
Accuracy (% of target) Precision (RSD%) Accuracy (% of target) Precision (RSD%) 
Conc A Conc B Conc A Conc B Conc A Conc B Conc A Conc B 
Tryptophan 0.996 10–10 nM -8.4 102 108 1 1 101 107 2 2 
Kynurenine 0.997 0.1–0.25 nM -4.1 96 115 1 1 95 114 1 3 
    KYNA 0.998 0.1–0.5 nM -12.1 102 106 1 1 102 106 2 1 
    3-HK 0.997 0.25–1 nM 23.4 94 91 1 2 95 92 1 2 
    XA 0.989 2.5–10 nM 6.0 95 85 2 2 97 86 7 3 
    3-HANA 0.963 1–5 nM -3.9 136 97 4 2 140 97 8 8 
    QUIN 0.998 2.5–5 nM 3.3 95 97 2 1 94 97 1 4 
    PIC 0.979 1–5 nM 12.5 112 89 3 5 113 87 4 1 
    NA 0.997 1–5 nM -4.0 101 96 9 1 97 95 2 1 
    NAA 0.996 2.5–10 nM 2.4 94 93 3 1 92 92 14 3 
Table 3. Linearity, LOD, LLOQ, matrix effect, accuracy and precision for intra-assay and for inter-assay results of validation of method for quantifying kynurenine metabolites in human CSF.  














Intra-assay (n = 6 during 20 h in +5°C) Inter-assay (n = 3) 
Accuracy (% of target) Precision (RSD%) Accuracy (% of target) Precision (RSD%) 
Conc A Conc B Conc A Conc B Conc A Conc B Conc A Conc B 
Tryptophan 0.999 6-6 nM -38.6 108.2 100.4 1.2 0.9 102.6 85.6 6 6.4 
Kynurenine 0.996 6-6 nM -23.3 108.5 113.1 0.7 2.3 114.8 105.2 2.8 13.6 
    KYNA 0.999 6-6 nM -36.7 90.7 91.8 1.8 0.6 87.9 98.0 10.8 6.9 
    3-HK 0.999 6-10 nM -54.5 96.3 87.0 1.9 1.2 87.3 85.2 9.5 5.0 
    XA 0.999 6-10 nM -18.5 100.6 100 5.2 1.4 86.3 105.6 3.7 6.5 
    3-HANA   0.999 6-10 nM 3.2 110.4 107.3 4.4 1.8 112.9 79.2 5.1 14.4 
    QUIN 0.999 6-10 nM -30 87.3 93.9 2.7 2.6 114.7 103.2 1.9 10.6 
    PIC 0.995 10-10 nM -50.5 90.2 99.8 2.4 0.9 86.9 96.0 6.5 7.6 
    NA 0.999 10-10 nM -26.3 104.8 95.9 1.4 1.6 112.5 94.4 9.3 4.5 
    NAA 0.996 6-10 nM -27.4 104.4 88.1 3.2 2.4 102.5 89.7 1.8 4.5 
Table 4. Linearity, LOD, LLOQ, matrix effect, accuracy and precision for intra-assay and for inter-assay results of validation of method for quantifying kynurenine metabolites in human plasma.  
Concentration A and B can be found in Table 2.  
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4.1.6 Stability  
Stability testing should be performed to ensure that bench-top storage at room temperature 
during sample preparation, analysis, and the storage conditions used, do not affect the 
metabolite concentration. The stability of kynurenine metabolites in human CSF and human 
plasma was evaluated for bench-top storage at room temperature and repeated freeze-thaw 
cycles.  
CSF 
We used CSF from 6 individuals with MS to test the kynurenine metabolite´s stability. The 
mean baseline concentrations of kynurenine metabolites in the CSF of those six subjects are 
presented in Table 5. All metabolites were found to be stable when stored at room temperature 
for 30 minutes, 1, 2, 3, and 4 hours, showing an average variance of a maximum of 13% (see 
Table 5). An average variance of a maximum of 7% was also seen for all metabolites after 2-5 
freeze-thaw cycles (see Table 6). 
We used CSF from 4 additional individuals with MS to test kynurenine metabolites stability 
after the first freeze-thaw cycle. The mean baseline concentrations of kynurenine metabolites 
in the CSF of those four subjects are presented in Table 7. After one freeze-thaw cycle, the 
percent stability showing an average variance of a maximum of 7%. Storing samples at room 
temperature for 24 hours resulted in a reduction of 3-HK concentration by 25% but did not 














Mean ± SD 
Storage in room temperature (n=6) expressed in % change 
30 min 1 h 2 h 3 h 4 h 
Tryptophan 1.5±0.5 µM 105 ± 4.9 105 ± 4.9 99 ± 4.9 101 ± 4.9 105 ± 4.9 
Kynurenine 60.2±30.6nM 95 ± 4.1 96 ± 4.1 93 ± 4.1 96 ± 4.0 100 ± 2.7 
KYNA 2.4±0.8 nM 113 ± 4.9 102 ± 4.9 89 ± 4.9 100 ± 4.7 109 ± 4.7 
3-HK 3.1±1.2 nM 99 ± 5.1 102 ± 2.9 97 ± 6.0 97 ± 4.1 102 ± 2.7 
QUIN 23.6±19.7nM 103 ± 5.9 106.2 ± 1.6 100 ± 4.6 101 ± 4.4 108 ± 2.5 
PIC 14.5±3.0 nM 98 ± 4.8 101 ± 4.2 96 ± 4.5 99 ± 4.0 104 ± 4.6 
NAA 22.8±20.9nM 100 ± 6.1 102 ± 1.9 96 ± 6.4 103 ± 7.2 111 ± 7.2 
Table 5. Percent stability of kynurenine metabolites in human CSF at room temperature after 30 





Mean ± SD 
Freeze-thaw (n=6) expressed in % change 
Thaw 2 Thaw 3 Thaw 4 Thaw 5 
Tryptophan 1.5 ± 0.5 µM 104 ± 4.9 100 ± 4.9 99 ± 4.9 101±4.9 
Kynurenine 60.2 ± 30.6 nM 98 ± 4.1 94 ± 4.1 94 ± 4.07 95±4.1 
KYNA 2.4 ± 0.8 nM 100 ± 4.9 96 ± 4.9 107 ± 4.9 101±4.9 
3-HK 3.1 ± 1.2 nM 103 ± 2.9 97 ± 1.7 97 ± 1.7 96±1.7 
QUIN 23.6 ± 19.7 nM 105 ± 1.5 101 ± 1.5 102 ± 5.9 100±5.9 
PIC 14.5 ± 3.0 nM 101 ± 4.7 97 ± 4.7 99 ± 4.6 101±6.3 
NAA 22.8 ± 20.9 nM 101 ± 2.3 98 ± 2.0 98 ± 7.6 105±6.6 
Table 6. Percent Stability of kynurenine metabolites in human CSF after 2-5 freeze-thaw cycles 






Mean ± SD 
1st freeze-thaw cycle & storage in room temperature for 
24 h (n=4) expressed in % change 
Thawing 1 24 h in room temperature 
Tryptophan 1.3 ± 0.1 μM 102 ± 3  95 ± 2.4 
Kynurenine 67.7 ± 57.7 nM 104 ± 4 95 ± 8.8 
KYNA 2.0 ± 0.4 nM 98 ± 2 99 ± 1.6 
3-HK 4.4 ± 3.2 nM 93 ± 4 75 ± 4.0 
QUIN 22.0 ± 3.6 nM 99 ± 2 111 ± 7.3 
PIC 9.2 ± 4.2 nM 100 ± 3 92.7 ± 4.3 
NAA 26.2 ± 10.4 nM 93 ± 8  104 ± 5.9 
Table 7. Percent stability of kynurenine metabolites in human CSF directly after of lumbar 
puncture (30 min after), after 24 h at room temperature (before any freezing), then again after 
one freeze cycle (mean ± SD). 
 
Plasma  
The mean baseline plasma concentrations of the metabolites from six subjects with MS are 
presented in Table 8. The majority of metabolites (8 out of 10) were found to be stable at 
room temperature up to 4 hours, showing an average variance of a maximum of 4%. XA and 
3-HANA were stable at room temperature for only up to 2 hours and showed an average 
variance of a maximum of 15% (see Table 8). An average variance of a maximum of 7% was 
also seen for all metabolites but XA, after 2-4 freeze-thaw cycles. Multiple freeze-thaw 
cycles reduced levels of XA by 20% (see Table 9). 
 
We used plasma from four healthy subjects to investigate the stability before the first freeze-
thaw cycle and after 24 h being stored at room temperature. Table 10 shows the mean baseline 
concentrations in fresh human plasma, analyzed within 30 minutes of blood drawing 
(followed by plasma isolation). The majority of metabolites (8 out of 10) were found to be 
stable when stored for 24 hours at room temperature showing an average variance of a 
maximum of 11%. QUIN and XA, on the other hand, increased by 32% and decreased by 
30% respectively (see Table 10).  
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All metabolites were stable after the first freeze-thaw cycle, having an average variance of a 
maximum of 10%. However, 3-HANA was an exception showing 26% average variation (see 





Mean ± SD 
Storage in room temperature (n=6) expressed in % change 
30 min 1 h 2 h 3 h 4 h 
Tryptophan 34.9 ± 4 µM  102.2 ± 2.9 102.3 ± 2.9 99.5 ± 2.5 100.5 ± 1.6 101.5 ± 1.9 
Kynurenine 2.4 ± 0.3 µM 102.4 ± 6.0 101.8 ± 4.8 99.6 ± 5.8 99.1 ± 1.7 101.1 ± 6.5 
KYNA 34.6 ± 13.3 nM  97.3 ± 7.1 97.1 ± 5.9 96.9 ± 7.0 96.7 ± 6.8 98.1 ± 6.1 
3-HK 27.8 ± 5.1 nM  100.7 ± 2.7 100 ± 4.6 97.5 ± 6.5 98.9 ± 3.2 102.3 ± 7.5 
XA 14.3 ± 7.6 nM  95.1 ± 52.1 85.7 ± 40.1 88.9 ± 42.7  80.5 ± 38.2 96.4 ± 54.8 
3-HANA 43.7 ± 37.5 nM  106 ± 10.3 104.7 ± 12.8 114.3 ± 12.7 109.7 ± 11.9 119.1 ± 13.2  
QUIN 161.7 ± 37 nM  102.1 ± 5.1 103.1 ± 6.1 100 ± 3.8 100.8 ± 5.7 103.6 ± 6.1 
PIC 36.8 ± 14.3 nM  100.2 ± 5.2 99.2 ± 3.4 100.9 ± 3.0 97.4 ± 5.6 99.5 ± 5.8 
NAA 178 ± 76.8 nM  101.7 ± 3.8 101.5 ± 4.9 101.7 ± 3.4 100.5 ± 4.4 101.4 ± 5.1 
Table 8. Percent stability of kynurenine metabolites in human plasma stored at room temperature 















Mean ± SD 
Freeze-thaw (n=6) expressed in % change 
Thaw 2 Thaw 3 Thaw 4 
Tryptophan 34.9 ± 4 µM  100.5 ± 1.9 99.9 ± 4.5 101 ± 1.4 
Kynurenine 2.4 ± 0.3 µM 101 ± 5.4 102.9 ± 6.5 100.1 ± 3.1 
KYNA 34.6 ± 13.3 nM  99.3 ± 2.4 99.7 ± 5.8 95.3 ± 7.9 
3-HK 27.8 ± 5.1 nM  101.3 ± 3 103.2 ± 3 97.8 ± 2.5 
XA 14.3 ± 7.6 nM  90.8 ± 49.6 86.7 ± 39.9 80.8 ± 40.2 
3-HANA 43.7 ± 37.5 nM  103 ± 6.8 106.7 ± 13.3 104.3 ± 9.5 
QUIN 161.7 ± 37 nM  100.5 ± 3.4 103.1 ± 9.8 98.4 ± 4.2 
PIC 36.8 ± 14.3 nM  100.1 ± 2.1 100 ± 3.5 101 ± 2 
NAA 178 ± 76.8 nM  101.8 ± 3.4 99.6 ± 4.4 102.5 ± 5.9 

















Mean ± SD 
1st freeze-thaw cycle & storage in room temperature for 
24 h (n=4) expressed in % change 
Thawing 1 24 h in room temperature 
Tryptophan 30.9 ± 5.3 µM  102 ± 1.3 98.0 ± 4.7 
Kynurenine 2.2 ± 0.3 µM 105.9 ± 6.0 93.7 ± 4.4 
KYNA 44.3 ± 10 nM 101.6 ± 2.2 97.6 ± 5.5 
3-HK 28.8 ± 7.6 nM 99.9 ± 3.2 88.7 ± 1 
XA 20.9 ± 6 nM 99.5 ± 2.7  69.5 ± 28.9 
3-HANA 29.6 ± 6.5 nM 126.4 ± 2.0 111.7 ± 3.9  
QUIN 144.5 ± 18.8 nM 110.2 ± 9.2 132.4 ± 5.1 
PIC 80.3 ± 33.1 nM 98.7 ± 1.6 95.2 ± 4.6 
NAA 130.2 ± 91.8 nM 107.7 ± 11.7 96.0 ± 0.04 
Table 10. Percent stability of kynurenines in human plasma directly after of blood drawing 
(followed by plasma isolation) (30 minutes after), after 24 hours being stored at room temperature 















4.2 Kynurenine metabolites in the CSF of patients with bipolar 
disorder and suicide attempters (Paper I, II) 
4.2.1 Decreased ratio PIC/QUIN in the CSF of suicide attempters  
In the CSF of 13 healthy controls and 13 suicide attempters, we successfully detected 
tryptophan, kynurenine, NAA, KYNA, 3-HK, QUIN and PIC. No differences regarding age, 
sex and BMI were found between healthy controls and suicide attempters (see Table 11). 
Suicide attempters had a mean of total SUAS score of 43.8 ± 17.0. 
 
 Healthy controls Suicide attempters P value a 
Age (years) b 40.4 ± 14.6 39.2 ± 15.6 0.49 
Sex (male/female) 5/8 7/6  
BMI c 24 (19 – 30) 26 (19 – 51) d 0.023 
Table 11. Demographic characteristics of the study population and kynurenine metabolites levels  
a Mann-Whitney test; b Mean ± SD; c median, IQR: Inter quartile range; d data missing for one subject  
 
Concentrations of tryptophan, kynurenine, NAA, KYNA, QUIN, 3-HK, PIC, and ratio 
kynurenine/tryptophan did not differ between suicide attempters and healthy controls (see 
Figure 4). The CSF PIC/QUIN ratio of suicide attempters was found to be lower than the CSF 
PIC/QUIN ratio of healthy controls (P = 0.03). Concentrations of CSF QUIN were higher in 
suicide attempters (P = 0.19) and concentrations of CSF PIC were lower in suicide attempters 
(P = 0.11), however, none reached statistical significance. Previously, we have shown that 
QUIN is elevated, and PIC is reduced in the CSF of suicide attempters (Erhardt et al., 2013; 
Brundin et al., 2016). Thus, CSF PIC and QUIN levels between suicide attempters and healthy 
controls were as hypothesized. The current findings support our original paper, where we also 
found a lower CSF PIC/QUIN ratio in suicide attempters (Brundin et al., 2016). However, 
studies in larger cohorts of suicide attempters are required to determine whether PIC, QUIN, 







Figure 4. Cerebrospinal fluid levels of kynurenine metabolites in healthy controls and 
suicide attempters.  
Levels of a) tryptophan, b) kynurenine, c) nicotinamide, d) 3-hydroxykynurenine, e) 
quinolinic acid, f) picolinic acid, g) kynurenic acid, h) ratio of kynurenine/tryptophan i) ratio 
of picolinic acid/quinolinic acid in the CSF of healthy controls and suicide attempters. Each 
point represents the concentration of a single CSF sample; the horizontal lines represent the 
































 3 Hydroxykynurenine 
Healthy 
controls








































































L-kynurenine / Tryptophan 
Healthy 
controls


















































Picolinic acid / Quinolinic acid 
Healthy 
controls






4.2.2 Kynurenine metabolites in the CSF of patients with bipolar disorder  
We measured CSF levels of tryptophan, kynurenine, KYNA, QUIN, and PIC in the CSF of 
101 patients with bipolar disorder and 80 healthy controls. Table 12 offers a summary of 




Healthy Controls (n = 80) Bipolar disorder patients (n=101) 
Age (years) 33 (27.3-43.8) 43 (35.5-54) <0.0001 a 
Sex (male/female) 39 / 41 40/61 0.22 b 
BMI1 (kg/m2) 23.48 (21.6-25.7) 25.33 (22.4-38.8) 2 0.003 a 
Nicotine (yes/no) 17/ 63 39/59 3 0.008 b 
Bipolar I disorder - n=45 - 
Bipolar II disorder - n=43 - 
Bipolar disorder NOS 4 - n=5 - 
Other diagnosis  n=7  
Lithium  - 53% - 
Topiramate  - 2% - 
Clonazepam  - 2% - 
Lamotrigine  - 14% - 
Valproate - 9% - 
Stimulant medication  - 17% - 
Antidepressant medication  - 42% - 
Anxiolytic medication  - 18% - 
Antipsychotic medication  - 33% - 
Sedative medication  - 39% - 
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Suicidal behavior 5 (yes/no) - 19/ 79 3  
MADRS 6 0 (0-2) (80) 2.5 (0-5.75) (98) 3 < 0.0001 
YMRS 7 0 (0-0) (80) 0 (0-1.75) (100) 2 < 0.0001 
CSF Tryptophan (µM) 1.5 (1.3-1.6) (80) 1.4 (1.2-1.7) (99) 8 0.73 c 
CSF L-kynurenine (nM) 32.9 (26.6-40.1) (80) 44.6 (32.5-62.1) (100) 2 0.06 c 
CSF KYNA (nM) 1.3 (0.9-1.7) (71) 9 1.7 (1.2-2.4) (99) 8 0.007 c 
CSF PIC (nM) 10.2 (6.6-14.0) (78) 8 13.3 (8.3-19.8) (101) 0.001 c 
CSF QUIN (nM) 18.2 (13.4-23.2) (80) 21.2 (15.4-29.1) (100) 2 0.48 c 
CSF kynurenine / tryptophan  22.2 (18.6-26.8) (80) 31.86 (23.0-39.8) (99) 8 0.04 c 
CSF PIC / QUIN  0.5 (0.3-0.9) (78) 8 0.5 (0.4-1.0) (100) 2 0.02 c 
Table 12. Clinical and demographic characteristics of the study participants  
a Mann-Whitney test; b Chi-square test; c Linear Mixed Model 1 Body mass index; 2Information 
missing for 1 subject; 3 Information missing for 3 subjects; 4 Bipolar disorder not otherwise 
specified; 5 Suicide attempt or self-harm; 6 Montgomery –Åsberg Depression Rating Scale; 7 
Young Mania Rating Scale;  8 Information missing for 2 subjects; 9 Information missing for 9 
subjects 
 
Subjects with bipolar disorder showed higher CSF levels of kynurenine, KYNA, PIC and also 
higher CSF kynurenine/tryptophan and PIC/QUIN ratio compared to healthy controls. CSF 
levels of tryptophan did not differ between patients with bipolar disorder and healthy controls 
This was an indication that kynurenine pathway activation is not substrate driven. In addition, 
this is supported by other studies showing that TDO2 is more expressed (Miller et al., 2004) 
and KMO is less expressed in patients with bipolar disorder (Lavebratt et al., 2014a). Increased 
CSF KYNA levels have been found in this cohort of patients with bipolar disorder is in line 
with our previous finding (Olsson et al., 2010; Olsson et al., 2012; Lavebratt et al., 2014; 
Sellgren et al., 2016; Sellgren et al., 2019). CSF sampling in the current study was done seven 
years after the CSF sampling in the previous studies from the same cohort.  In addition, PIC 
and ratio PIC/QUIN that were found to be elevated in CSF of patients with bipolar might be 
because of a possible activated immune system in the brain of those subjects, resulting in an 
activated kynurenine pathway, since IFN- γ, IL-1 β as well as IL-8, that are increased in those 
patients with bipolar, are known to induce both IDO and TDO2 (Söderlund et al., 2011; Isgren 
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et al., 2015; Isgren et al., 2017). All in all, the kynurenine pathway is activated in bipolar 
disorder and the activation is not substrate driven. It would be interesting to explore what would 
happen in case of bipolar patients undergo a diet of high tryptophan, having evidence that 
increased tryptophan intake in the diet can affect depression and mood state scores in healthy 
participants, resulting in improved mood states and less depressive symptoms (Lindseth et al., 
2015).  
 
4.2.3 Decreased levels of CSF PIC in patients with bipolar disorder with 
suicidal behavior  
We further investigated if CSF levels of kynurenine metabolites were associated with suicidal 
behavior in bipolar patients. We found that CSF levels of tryptophan were higher (P = 0.03) 
while CSF levels of PIC (P = 0.048) and the ratio kynurenine/tryptophan  (β = −0.08, P = 0.04) 
were lower in patients with bipolar disorder with a history of suicidal behavior compared to 
patients without any history of suicidal behavior. No differences in CSF kynurenine, KYNA, 
QUIN, or the PIC/QUIN ratio levels was found between the groups.  
In our previous studies, we showed suicide attempters have reduced concentration of PIC in 
the CSF (Brundin et al., 2016) and remained reduced up to two years after. CSF QUIN levels 
were found to be elevated when subjects attempt suicide and have returned to normal six 
months later (Erhardt et al., 2013; Bay-Richter et al., 2015). Here we show that the 
concentration of PIC in CSF was reduced in bipolar patients who had a history of suicidal 
behavior compared to bipolar patients who did not have such a history. The QUIN levels in 
CSF did not differ in these sub-groups, a finding supporting the hypothesis that QUIN is only 
elevated at the time of the attempt. Importantly, in this study lumbar puncture was performed 
between one and seven years after the suicidal attempt. 
Studies have shown that a combination of PIC and the mineral chromium called chromium 
picolinate helps subjects with atypical depression (Davidson et al., 2003; Docherty et al., 2005). 
Although the aim has not been to raise PIC levels, the metabolite´s subsequent elevation may 
help to partly clarify why the subjects´ symptoms improved. Low levels of PIC have also been 
reported in the plasma of subjects with unipolar depression, ETC treatment leads to elevated 
levels of PIC (Aarsland et al., 2019; Ryan et al., 2020). In addition, Radix Bupleuri-Radix 
Paeoniae Alba (RB-RPA), which is an herbal mix used for depression treatment, increases the 





Figure 5. Cerebrospinal fluid levels of kynurenines in patients with bipolar disorder 
without and with suicidal behavior.  
CSF levels of a) tryptophan, b) kynurenine, c) KYNA, d) QUIN, e) PIC, f) ratio 
kynurenine/tryptophan, g) ratio PIC/QUIN in patients with bipolar disorder that did not have 
suicidal behavior and the ones that had suicidal behavior. Each point represents the 
concentration of a single CSF sample, the horizontal lines represent the median for each group, 












































































































































































4.2.4 Associations between pharmacological treatment and kynurenine 
metabolites in CSF of patients with bipolar disorder 
The most commonly prescribed pharmacological treatments for patients with bipolar disorder 
are antidepressant drugs, antipsychotic drugs, lithium, lamotrigine, and valproate. Here, we 
investigated if different pharmacological treatments affected the levels of kynurenine 
metabolites in the CSF of patients with bipolar disorder.  
Antidepressant drugs  
Patients with bipolar disorder that received antidepressant drug treatment (n=42) had elevated 
CSF levels of kynurenine, KYNA, and  higher kynurenine / tryptophan ratio (kynurenine: β = 
0.3, P = 0.02; KYNA: β = 0.92, P = 0.001; kynurenine/tryptophan: β = 0.06, P = 0.02) than 
patients that did not receive antidepressant drug treatment (n=59). We did not find any 
differences for the other metabolites measured (tryptophan: P = 0.53; QUIN: β= 0.02, P = 0.45; 
PIC: P = 0.64; ratio PIC/QUIN: β= 0.33, P = 0.39) (Figure 6).  
Antipsychotic drugs 
Antipsychotic drugs did not affect the CSF levels of any kynurenine pathway metabolites 
(tryptophan: P = 0.59; kynurenine: β= −0.009, P = 0.45; KYNA: β = 0.0001, P = 1.0; QUIN: β 
= 0.32, P = 0.20; PIC: P = 0.29; ratio kynurenine/ tryptophan: β = 0.008, P = 0.71; ratio 
PIC/QUIN: β = −0.43, P = 0.32). 18 patients with bipolar disorder were treated with 
antipsychotics, while 83 were not.  
Lamotrigine 
When we compared patients with bipolar disorder who used lamotrigine (n=14) to those who 
did not (n=87), we found that only kynurenine was elevated in the ones that used lamotrigine 
(β = 0.04, P = 0.03). The other kynurenine metabolites showed no differences  (tryptophan: P 
= 0.07; KYNA: β = 0.40, P = 0.13; PIC: P = 0.08; QUIN: β = − 0.02, P = 0.64; ratio kynurenine/ 
tryptophan: β = 0.03, P = 0.21; ratio PIC/QUIN: β= 0.84, P = 0.09). 
Lithium 
CSF levels of kynurenine pathway metabolites between patients with bipolar disorder who used 
lithium (n=54) and those who did not (n=47) did not differ (tryptophan: P = 0.15; kynurenine: 
β = 0.02, P = 0.16; KYNA: β= 0.17, P = 0.38; QUIN: β= 0.01, P = 0.54; PIC: P = 0.17; ratio 




There were no differences in CSF kynurenine pathway metabolites between patients with 
bipolar disorder who used valproate (n=9) and those who did not (n=92) (tryptophan: P = 0.2; 
kynurenine: β = −0.006, P = 0.81; KYNA: β = −0.08, P = 0.87; QUIN: β = −0.18, P = 0.09; 
PIC: β = −0.12, P = 0.82; ratio PIC/QUIN: β = 0.91, P = 0.13). 
The associations we found between antidepressant treatment and elevated kynurenine and 
KYNA levels in CSF, and also between treatment with lamotrigine and elevated kynurenine 
levels in CSF, are supported by rodent studies. When rodents were treated with antidepressants 
that selectively inhibit serotonin reuptake, reduced KMO gene expression, elevated astrocytic 
KAT1 and KAT2 gene expression as well as lower QUIN brain levels were seen (Kocki et al., 
2012; Eskelund et al., 2017). Thus, antidepressant therapeutic efficacy might be enhanced by 
directing the kynurenine pathway's activity toward the development of the NMDA receptor 

















Figure 6. Cerebrospinal fluid levels of kynurenines in patients with bipolar disorder not 
using and using antidepressant drugs.  
CSF levels of a) tryptophan, b) kynurenine, c) KYNA, d) QUIN e) PIC f) ratio 
kynurenine/tryptophan, g) ratio PIC/QUIN in subjects with bipolar disorder not using 
antidepressants and using antidepressants. Each point represents the concentration of a single 
CSF sample, the horizontal lines represent the median for each group, and the bars represent 


















































































































































































4.2.5 Associations between CSF kynurenine metabolites and symptoms  
MADRS and YMRS scores did not correlate with any of the metabolites in the CSF of 
patients with bipolar disorder. Moreover, the number of depressed, manic, hypomanic, or 
mixed episodes did not correlate to any of the kynurenine metabolites. We found a 
tendency towards a negative correlation between the number of manic episodes and the 
CSF KYNA concentration ( r = −0.21, P = 0.06). 
 
Age of patients 
with bipolar 
disoder  
Number of mood episodes (median, IQR) Duration of 
illness in years 
(median, IQR) Depressive Hypomanic Manic Mixed 
<35 
(n=26) 
8 (3-12.5) 2 (0.5-5) 1 (1-3.5) 0 (0-0) 17 (13.5-19) 
36-50 
(n=41) 
6 (3-17) 6 (2-29) 1 (1-4.25) 0 (0-1) 22 (19-25) 
51< 
(n=34) 
7 (3-14) 2.5 (0.25-8.75) 1 (0-4) 0 (0-0) 
35.5 (24.25-
45.25) 
Table 13. Summary of mood episode history of patients with bipolar and their duration of 
illness  
 
4.2.6 Common genetic variation in ACMSD and suicidal behavior  
In genotyped patients with bipolar disorder (n=99) we explored the effects of ACMSD variants 
(tag SNPs) on CSF QUIN, PIC, and the PIC/QUIN ratio. The SNPs rs6722883 associated 
negatively with the CSF PIC/QUIN ratio of bipolar disorder patients with a history of suicidal 
behavior (n=19) after controlling for age, sex, and post-hoc Bonferroni correction: (β = −1.77; 
P = 0.001). Thus, the negative association found here between the tag SNPs rs10928521 and 
rs6722883 and the ratio PIC/QUIN is supporting the results from our previous study (Brundin 
et al., 2016) showing that specific polymorphisms of the ACMSD gene associate with higher 




4.3 Kynurenine metabolites in the CSF and plasma of healthy 
subjects following physical exercise (Paper III, IV) 
4.3.1 Sprint interval training  
Participants of the study were divided into old subjects 64.3±5.7 years old (mean±SD) and 
young subjects 24±3.2 years old (mean±SD). Plasma was collected before SIE (baseline), one 
and 24 hours after the SIE was performed. Baseline levels of kynurenine metabolites did not 
differ between young and old participants (see Table14). 
 
Compound Young baseline Old baseline P values* 
Tryptophan 43.8 µM ± 4 43.7 µM ± 4.3 0.97 
Kynurenine 2.5 µM ± 0.2 3.0 µM ± 0.3 0.25 
KYNA 49.5 nM ± 5.4 56.2 nM ± 15.1 0.63 
3HK 33.7 nM ± 4.4 43.6 nM ± 8.9 0.35 
QUIN 422.0 nM ± 61.4 404.8 nM ± 62.1 0.84 
PIC 58.4 nM ± 7.4 92.1 nM ± 29.1 >0.99 
NAA 127 nM ± 18.8 97.6 nM ±9.6 0.25 
Table 14. Baseline levels of kynurenine metabolites in young and old subjects                       
*Mann-Whitney U-test (mean ± SEM) 
 
One bout of SIE did not affect any of the metabolites in the plasma of young subjects at any of 
the timepoint tested (see Figure 3). In old subjects, plasma kynurenine levels were found to be 
elevated one hour after the bout of SIE (P = 0.03) (Figure 3d) and plasma KYNA levels 
significantly elevated 24 hours after (P = 0.02) (Figure 7d). The other kynurenine metabolites 
were not affected by SIE.  
Kynurenine and KYNA changes seen only in old subjects might be due to the higher relative 
SIE intensity since the SIE intervention in this study was related to body weight, and the muscle 






Figure 7. Plasma concentrations of kynurenines at baseline, 1 hour and 24 hours after 
SIE, in young (green) subjects and in old (red) subjects.  
Each dot represents the concentration of respective metabolite in nM (µM for tryptophan and 
kynurenine) of a single plasma sample. A dotted line is used when a timepoint data is missing 



















































































































































































































































































































































































































































































4.3.2 Aerobic exercise  
Tryptophan, kynurenine, KYNA, 3-HK, PIC and QUIN were analyzed in the CSF and plasma 
of 27 subjects. Subjects were sub-grouped based on their exercise habits. Thus, 14 subjects 
were placed to the acute exercise group and 13 allocated to the training exercise group. All 
kynurenine metabolites were successfully detected in 26 subjects. Both baseline and follow-up 
exercise CSF from one subject had a coefficient of variation more than 10%  in the detection 
of duplicates for PIC, so it was excluded from the statistical analyses. A summary of 
participants characteristics is presented in Table 15.  
 Total study sample 
(n=27) Acute group (n=14) Training group (n=13) 
Sex (male/female) 12/15 6/8 6/7 
Age (years) a 28.7±7.7, 22–52 28.1±8.7, 22–52 29.3±6.8, 22–45 
Body Mass Index 
(kg/m2) a 22.6±2.6, 18.9–29.6 22.9±2.7, 19.6–29.6 22.2±2.5, 18.9–28.0 
Smokers 0 0 0 
History of or active 
substance use disorder 0 0 0 
Continous medication 0 0 0 
Exercise habits b  







Table 15. Characteristics of the study population. 
Individuals that participated in the study were allocated in two groups based on their exercise habits.       
a Mean ± SD., range. b Self-reported measure of recent exercise activity.  
 
CSF concentrations of KYNA, 3HK and PIC levels were increased after the acute exercise 
paradigm, while tryptophan and kynurenine remained unchanged. Moreover, the CSF ratio of 
kynurenine/tryptophan increased in the training group. On the contrary, tryptophan and 
kynurenine strongly decreased after acute exercise, whereas KYNA, 3-HK, QUIN and PIC in 





Figure 8. Cerebrospinal fluid and plasma concentration of kynurenine metabolites 
stratified by exercise intervention.  
Box and dot plots illustrate metabolite levels (μM) in a) cerebrospinal fluid (CSF) and b) 
plasma among paired samples (line) baseline and follow-up moderate or high intensity 
anaerobic exercise. Significance was determined for all samples (dotted bar) and when 




Correlations between CSF and plasma concentrations of kynurenine metabolites were in 
general weak. Interestingly though, PIC and showed a strong correlation between CSF and 
plasma both at baseline and follow up (see Figure 9).  
 
 
Figure 9. Heatmaps showing the correlation between metabolites analyzed in 
cerebrospinal fluid with those in plasma.  

















4.3.3 Neurotransmitters in the CSF of healthy subjects  
Concentrations of the neurotransmitters glutamate and GABA analyzed at the baseline and 
follow up-intervention did not change in either groups. CSF serine levels were though found 
to be elevated following acute exercise intervention (Figure 10).  
 
Figure 10. Box and dot plots representing (A) glutamine, (B) GABA and (C) serine levels 
(μM) in cerebrospinal fluid (CSF) among paired samples (line) at baseline and follow-up 
training or acute exercise.  
* P < 0.05, ** P < 0.01, and *** P < 0.005. 
 
4.3.4 Immune markers in the CSF and plasma of healthy subjects  
PEA was used to investigate a panel of 92 inflammation-related proteins in both CSF and 
plasma. Only proteins with a paired call rate > 70% were used for further analysis (CSF n = 
47; plasma n = 68). One marker (BDNF) was excluded due to issues with assay reliability. 
Three out of the 47 proteins were found to be upregulated in the CSF of subjects performing 
acute physical exercise. On the contrary, no changes were found after the training exercise 
intervention (Figure 11 A, B). After the acute exercise program 12 out of 68 proteins were 
upregulated in plasma, although, again, no changes were found after the training exercise 
intervention (Figure 11 C, D). We found only minor differences in baseline protein levels in 





Figure 11. Changes in the immune marker profile of cerebrospinal fluid (CSF) and 
plasma after training and acute intervention exercise.  
Volcano plots show the mean difference and significance (P) from paired Student t-tests 
comparing baseline and follow-up levels of immune markers in CSF (A,B), plasma (C,D), and 
the ratio of CSF/plasma (E,F), after intervention with training (left) or acute (right) intensity 
exercise. The red dashed line indicates an exploratory cutoff of P=0.05 and associations with 
PFDR <0.05 are presented as red dots. 
 
 71 
In detail, CSF vascular endothelial growth factor (VEGF) was found to be upregulated after 
the acute exercise. In line with this, one study showed that VEGF levels in the blood rise in 
proportion to the exercise intensity (Marquez et al., 2015). There was only one protein 
upregulated in both plasma and CSF after acute exercise and it was matrix metalloproteinase 
(MMP)-10. Upregulation of MMP-2 and MMP-9 has previously been associated with the 
exercise of high intensity (Carmeli et al., 2005). We found that CSF IL-7,  and plasma 
transforming growth factor-alpha, delta, leukemia inhibitory factor receptor, and notch-like 
epidermal growth factor, were all increased after the acute exercise, however, none of those 
had previously been shown to have an association with physical exercise. In addition, some 
cytokines and chemokines were increased in plasma after acute exercise, however, that was not 
the case for CSF.  
 
4.3.5 Relation CSF-plasma of kynurenine metabolites and immune markers 
in healthy subjects  
To investigate if changes in immune markers in plasma and CSF after the physical exercise 
correlated with changes in kynurenine metabolites, two exercise groups were combined. We 
found that in the CSF of subjects after exercise kynurenine, QUIN, kynurenine/tryptophan 
ratio, and less the PIC/QUIN ratio correlated with an aberrant profile of immune markers. We 
also found that in plasma of subjects after exercise kynurenine and PIC, and less KYNA 












Figure 12. Correlation between levels of immune related protein and kynurenines 
Volcano plots summarize the effect size (B) and significance (P) from linear regression 
analyses between metabolite and protein levels adjusted for age at baseline, sex, intervention, 
and sample handling variability. Red dashed line indicates an exploratory cutoff of P=0.05 and 
associations with PFDR <0.05 are presented as red dots.
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Figure 13. An overview schematic illustration of the workflow of the thesis 
(created with Biorender.com) 
 
In the present thesis, we have developed a robust, sensitive, and reproducible method to detect 
and simultaneously quantify ten kynurenine metabolites in human CSF and plasma using 
UPLC-MS/MS. Importantly, our method provides clear chromatographic separation of the two 
isomers PIC and NA. Thus, our newly developed method has several advantages compared to 
other methods used for analyzing kynurenines. In addition, the simultaneous analysis of such 
many metabolites allows for a minimum volume.   
In order to use kynurenine pathway metabolites as biomarkers on a daily basis in the clinic, it 
is of essential importance to know how stable the metabolites are. Our results show that, in 
general, the metabolites are very stable both in CSF and plasma. They are thus, stable at room 
temperature for up to 4 hours and they do not degrade following multiple freeze-thawing. Long-
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term storage (up to 24 hours) at room temperature might though affect CSF 3-HK 
concentrations and plasma QUIN levels. In addition, data presented in this thesis suggest that 
plasma 3-HANA and XA concentration might increase following 2-3 hours of being stored at 
room temperature.  
Biomarkers are becoming increasingly important in all fields of clinical practice, as they may 
be used to diagnose, monitor, or predict illness at any stage during patient care. This is of 
particular importance in psychiatry (Le-Niculescu et al., 2021), where the diagnose is solely 
based on symptoms. Biomarkers may thus provide an objective, measurable way to 
characterize the disease. Several of the kynurenine pathway metabolites have been suggested 
as putative future biomarkers for psychiatric disorders. Thus, previous studies have shown that 
QUIN is increased, and PIC is decreased in the CSF at the time of suicide attempt. While CSF 
QUIN levels return to normal levels within 6 months after the attempt, CSF PIC levels remain 
low throughout a period of two years after the suicide attempt (Erhardt et al., 2013; Brundin et 
al., 2016). Low CSF PIC is thus suggested to indicate vulnerability for suicidal behavior 
(Brundin et al., 2016). In the present thesis, we confirm a low PIC/QUIN ratio in the CSF of 
suicide attempters compared to healthy controls. Interestingly, we also discovered that CSF 
PIC levels were lower in a sub-group of patients with bipolar disorder with a history of suicidal 
behavior, compared to bipolar disorder patients that had not experienced suicidal behavior. In 
line with the hypothesis that CSF QUIN levels are only elevated at the time of a suicide attempt, 
the CSF QUIN levels were similar to the levels in healthy controls. In the bipolar disorder 
cohort, we further confirmed that CSF KYNA levels are increased compared to healthy 
controls.  
Previous studies suggest that the imbalance between QUIN and PIC might be related to lower 
expression and/or lower activity of the enzyme ACMSD in suicide attempters (Brundin et al., 
2016). In the present thesis, we also found that genetic variations in the ACMSD gene 
contribute to this imbalance. As such, the enzyme ACMSD might be a potential therapeutic 
target for suicidal behavior. When developing a biomarker, it is of importance to have control 
of confounding factors. Indeed, several studies have shown that physical exercise affects the 
levels of peripheral kynurenine pathway metabolites. However, there is limited information on 
how physical exercise affects brain levels of the metabolites and if central levels correlate to 
levels in the periphery. In the present thesis, we present data on how SIE affects plasma levels 
of kynurenine pathway metabolites in different age groups of healthy subjects. In addition, we 
show how aerobic exercise affects central and peripheral levels of these metabolites in healthy 
subjects. Thus, one bout of SIE increased plasma kynurenine and KYNA levels in old, but not 
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young, healthy subjects. The disparity between young and old subjects is believed to be related 
to skeletal muscle physiology (Westbrook et al., 2020). Thus, muscle mass, known to decrease 
with age (Heo et al., 2018), indicates that the relative training intensity was higher in older 
subjects. The different effects may also be related to age-related variations in immune activity  
(Walston et al., 2002; Varadhan et al., 2014). Different intensity of aerobic exercise was also 
found to affect kynurenine pathway metabolites in both plasma and CSF. In addition, we found 
minor changes in immune markers, and in line with data showing immune-induced activation 
of the kynurenine pathway, we found that several of the immune markers correlated with the 
concentrations of kynurenine pathway metabolites. Generally, though, we found no correlation 
between plasma and CSF levels of immune markers or between kynurenine pathway 
metabolites in the CSF and plasma. The only exception was PIC, which showed a high 
correlation between plasma and CSF, both before and after exercise. This is interesting in view 
of the fact that low plasma PIC levels are also found in suicide attempters  (Brundin et al., 
2016).  
According to FDA, there are seven categories of biomarkers; risk, diagnostic, prognostic, 
predictive, pharmacodynamic, safety, and monitoring biomarkers. Analyzing the feasibility of 
using PIC as a biomarker for suicide and/or suicidal behavior in patients with bipolar disorder 
–  diagnostic, risk, prognostic, and predictive biomarkers might be the case. Using a diagnostic 
biomarker, first suicide should be classified as a novel diagnosis and second a cut-off value 
must be set. Also using a risk biomarker, suicide should be considered a diagnosis itself. PIC  
as a prognostic biomarker could be the case of suicidal behavior as a preexisting condition in 
patients with bipolar disorder. In such cases, the basal level for the biomarker should be 
established. In addition, prognostic biomarkers should be specific for the present diagnose, i.e., 
it should be specific for bipolar disorder and no other psychiatric diagnoses. Predictive 
biomarkers instead are used to distinguish subjects who have the highest chance of responding 
positively to a given intervention. In conclusion, our data support the hypothesis that PIC could 
be developed into a potential biomarker indicating vulnerability for suicide behavior.  
In conclusion, by using a newly developed method for analyzing kynurenine pathway 
metabolites, we here confirm an activated kynurenine pathway in the brain of bipolar disorder 
patients. We also find support for the hypothesis that low PIC levels could be a marker 
indicating vulnerability for suicidal behavior and we show that exercise influences both central 
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